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ABSTRACT 
Multiple Sclerosis (MS) is an autoimmune inflammatory disease of the central nervous 
system (CNS) predominantly mediated by self-reactive T and B cells. T cells have been long 
considered as major players in disease development. However, the success of B cell depletion 
therapies in MS patients highlights a complex role of B cells in disease initiation and 
progression. B cells can have both proinflammatory and regulatory effects. They can produce 
potentially pathogenic autoantibodies, act as antigen-presenting cells (APCs), and/or secrete 
cytokines shaping the local milieu. Actively induced Experimental Autoimmune 
Encephalomyelitis (EAE), the most common animal model of MS, is not optimally suited to 
study the role of B cells in autoimmune responses, as immunization with myelin peptide 
bypasses antigen processing and presentation by B cells. However, spontaneous EAE (sEAE) 
mouse models featuring transgenic T cell receptors (TCRs) specific for myelin 
oligodendrocyte glycoprotein (MOG) develop B cell-dependent disease, and can thus provide 
insights into the role of B cells in initiation of pathogenesis. To evaluate when and where B 
cells become activated in sEAE possible activation sites were investigated with different 
methodological approaches. First, we tried to determine whether myelin proteins from the 
CNS are transported to cervical lymph nodes (CLNs) in soluble form or via exosomes in 
spontaneous relapsing-remitting EAE (TCR1640 mice) to investigate if autoreactive B cells are 
activated directly in CLNs. Alternatively, B cells might be activated in a different place and 
recruited to CLNs. Therefore, we explored the intestine as a potential site for priming of auto-
reactive B cells via B cell transfer and activation studies. However, as B cell analysis ex vivo 
and functional studies were not feasible due to low B cell frequencies in the intestine after 
transfer, in this study we focused on establishing a new B cell culture system, allowing 
expansion, differentiation, and manipulation of primary B cells and testing the use of this 
system for studying pathogenic properties of B cells upon transfer in vivo. After successful 
establishment of in vitro induced germinal center B cell (iGB) culture, we adoptively 
transferred MOG-specific iGB cells (from a mouse model expressing a MOG-specific BCR, 
called TH mouse), into 2D2 mice, which carry a transgenic MOG-specific TCR, to test their 
pathogenic potential. Results demonstrated that MOG-specific iGB cells can trigger 
development of EAE. These data support a role of B cells in the initiation of EAE probably 
acting as APCs. In summary, the new B cell culture system is a unique tool to expand and 
manipulate B cells and thereby characterize their role in the development of EAE and MS.  
ZUSAMMENFASSUNG V 
ZUSAMMENFASSUNG 
Multiple Sklerose (MS) ist eine entzündliche Autoimmunerkrankung des zentralen 
Nervensystems (ZNS), die überwiegend durch selbstreaktive T- und B-Zellen vermittelt wird. T-
Zellen wurden lange als Hauptakteure bei der Krankheitsentwicklung betrachtet. Jedoch weist 
der Erfolg von B-Zell-Depletionstherapien bei MS-Patienten auf eine komplexe Rolle der B-Zellen 
im Krankheitsverlauf hin. B-Zellen können sowohl proinflammatorische, als auch regulatorische 
Effekte haben. Sie produzieren potentiell pathogene Autoantikörper, wirken als Antigen 
präsentierende Zellen und/oder sezernieren Zytokine, die das lokale entzündliche Milieu prägen. 
Die aktiv induzierte experimentelle Autoimmunenzephalomyelitis (EAE), ein MS Tiermodell, ist 
nicht gut geeignet, um die Rolle der B-Zellen während der Autoimmunantwort optimal zu 
studieren, da die Antigen-Prozessierung und Präsentation durch B-Zellen bei der Immunisierung 
mit Myelin-Peptiden umgangen wird. Allerdings können spontane EAE (sEAE) Mausmodelle, wo 
es unter anderem zu Rekrutierung endogener autoreaktiver B-Zellen kommt, Einblicke in die Rolle 
der B-Zellen in der Pathogenese gewähren. Um zu verstehen, wann und wo autoreaktive B-Zellen 
in sEAE aktiviert werden, wurden mögliche Aktivierungsorte mit verschiedenen 
methodologischen Ansätzen untersucht. Zuerst wurde getestet, ob in spontaner schubförmiger 
EAE (TCR1640 Mäuse) Myelinproteine in löslicher Form oder über Exosome aus dem ZNS zu den 
zervikalen Lymphknoten (ZLK) transportiert werden, um B-Zellen direkt in den ZLK zu aktivieren. 
Alternativ könnten B-Zellen an einem anderen Ort aktiviert und dann in ZLK rekrutiert werden. 
Daher wurde das Priming von autoreaktiven B Zellen im Darm mit B Zell-Transfer und 
Aktivierungsstudien untersucht. Da jedoch eine aussagekräftige Analyse durch niedrige B Zell-
Frequenzen im Darm nach dem Transfer nicht realisierbar erschien, wurde der Fokus dieser Arbeit 
auf die Etablierung eines neuen B-Zellkultursystems gelegt, welches die Expansion, 
Differenzierung und Manipulation von primären B-Zellen ermöglicht, sowie auf die Nutzung des 
Kultursystems für die Untersuchung pathogener Eigenschaften von B-Zellen nach Transfer in vivo. 
Nach erfolgreicher Etablierung von in vitro induzierten Keimzentrums B-Zellen (iGB) wurden 
MOG-spezifische iGB-Zellen (aus der TH Maus, welche einen MOG-spezifischen B Zellrezeptor 
besitzt) in 2D2 Mäuse, die einen transgenen MOG-spezifischen T-Zellrezeptor tragen, adoptiv 
transferiert, um ihr pathogenes Potential zu untersuchen. Die Ergebnisse zeigten, dass MOG-
spezifische iGB Zellen eine EAE auslösen können. Diese Daten unterstützen eine Rolle der B-Zellen 
bei der Initiierung von EAE, wobei sie wahrscheinlich als Antigen-Präsentierer agieren. 
Zusammenfassend ist das neue B-Zellkultursystem ein einzigartiges Werkzeug, um B-Zellen zu 
expandieren und zu manipulieren, und so ihre Rolle bei der Entwicklung von EAE und MS zu 
charakterisieren. 
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1 INTRODUCTION  
1.1 Multiple Sclerosis  
Multiple sclerosis (MS) is a chronic inflammatory disease of the spinal cord and brain 
affecting approximately 2.5 million people worldwide with increasing numbers [1]. Clinical 
manifestations of this autoimmune disease are sensory and visual disturbances, motor 
impairments, fatigue, pain and cognitive deficits [2]. The clinical manifestations correlate 
with active lesions in the CNS. These lesions are caused by immune cell infiltration across 
the blood-brain barrier (BBB) promoting inflammation, demyelination, gliosis and 
neuroaxonal degeneration [3]. The current concept is that autoreactive T and B cells are 
the main drivers of disease progress, and thus, common therapies are 
immunomodulatory drugs. Unfortunately, they are often associated with several strong 
side effects from development of other autoimmune disorders and malignancies to fatal 
infections [4]. This indicates the important need to identify more specific therapeutic 
targets. However, deeper knowledge about molecular mechanisms in immunopathology 
of MS is required. 
The most common form affecting approximately 85% of patients is relapsing-remitting 
MS [5]. This form is characterized by an initial episode where the patient shows 
neurological dysfunction, followed by a remission period of clinical recovery. Most 
patients (80%) develop after several relapses a secondary progressive MS, where lesions 
are no longer characteristic, and instead neurological dysfunction is accompanied by 
decreased brain volume and increased axonal loss, also called CNS atrophy [6]. Only 10% 
of patients develop primary progressive MS featuring progressive decline from the outset 
and the absence of relapses [4]. MS usually appears in adults in their late twenties or early 
thirties but it can rarely start in childhood and after 50 years of age [2, 7]. The primary 
progressive subtype is more common in people in their fifties [8]. Similar to many other 
autoimmune disorders, the disease is more common in women, and the trend to disease 
development may be increasing [9].  
Another form of demyelinating disease is Neuromyelitis optica (NMO), also known as 
Devic's disease. This disease actually comprises a spectrum of disorders characterized by 
simultaneous inflammation and demyelination of the optic nerve (optic neuritis) and the 
spinal cord (myelitis), whereas the brain is largely spared. Inflammatory lesions are 
different from those observed in MS. Most patients with NMO have been found to have 
no or very few nonspecific white matter lesions on brain MRI. Spinal cord MRI also shows 
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distinctive findings: a majority of patients have extensive longitudinal lesions covering 
three or more vertebral segments. Furthermore, NMO patients frequently have CSF 
pleocytosis of more than 50 leukocytes per μl, with or without the presence of neutrophils 
[10]. Aquaporin 4 (AQP4) antibody, an autoantibody that binds to the water channel 
AQP4, in combination with diagnostic criteria support the distinction of NMO from other 
autoimmune disorders of the CNS [11]. However, not all NMO patients have AQP4 
antibodies. There is a subgroup of patients, which are negative for AQP4 but positive for 
myelin oligodendrocyte protein (MOG) antibodies, but this seems to be rare [12]. 
1.1.1 Etiology 
The exact cause of MS remains elusive. Genetic variation accounts for approximately 30% 
of the overall disease risk, however, environmental factors and/or immunological 
heterogeneity in general also greatly contribute to the risk [13, 14]. The majority of MS 
related genes are immunological, thus, the human leukocyte antigen (HLA), located 
within the major histocompatibility complex (MHC) region, has been consistently 
associated with MS in all populations tested [15]. Other genes are tumor necrosis factor 
receptor 1 (TNFR1), interferons (IFNs), interleukin-2 (IL-2) and NFĸB [16, 17]. The data 
implicate central and peripheral tolerance mechanisms, as well as peripheral differences 
in effector T cell function [4]. Considering that the numerous genetic risk factors for MS 
probably affect a multitude of immunological pathways, environmental factors that 
influence any of these different pathways may also contribute to disease development. 
Several environmental risk factors have been reported including vitamin D, human 
cytomegalovirus infection, circadian disruption, smoking, and Epstein-Barr virus (EBV) 
infection [18, 19]. Moreover, a relatively new link between MS and diet/gut microbiota 
has been proposed which will be discussed in 1.3.3.  
1.1.2 Pathogenesis 
An open question is wether MS is triggered in the periphery or in the CNS. In the 
peripheral model, autoreactive T cells and B cells are activated in secondary lymphoid 
organs potentially through release of previously sequestered CNS antigen, molecular 
mimicry, bystander activation or co-expression of TCRs with different specificities [4, 20]. 
Molecular mimicry is defined as a theory where sequence similarities between foreign 
and self-peptides or proteins are sufficient to result in the cross-activation of autoreactive 
T or B cells by a foreign antigen [21, 22]. In bystander activation, T cells are activated in 
absence of specific TCR stimulation or stimulation, which allows T cells to bypass 
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checkpoints of central and peripheral tolerance. After activation, these autoreactive T 
cells traffic to the CNS as a primary phenomenon, become re-activated through contact 
with autoantigen, and initiate an inflammatory cascade attracting other cells including 
more T cells, B cells and monocytes.  
Alternatively, in CNS-triggered disease development, the infiltration of autoreactive B and 
T cells occurs as a secondary phenomenon while inflammation and demyelination are 
already established in the CNS by other immune cells for example monocytes and 
neutrophils. Studies in the EAE model indicate that these cell types are enriched among 
CNS infiltrating cells during the preclinical phase and could play a role in nascent lesion 
development by mediating BBB and blood-cerebrospinal fluid (CSF) barrier breakdown, 
and/or by stimulating the maturation of local APCs [23-25]. 
All together, MS is a heterogeneous autoimmune disease which involves genetic as well 
as environmental factors leading to dysfunction of checkpoint mechansims and escape of 
autoreactive or defect immune cells which can initiate attack on self proteins. 
1.2 Experimental Autoimmune Encephalomyelitis 
1.2.1 Actively induced EAE mouse model 
To identify new therapeutic approaches for MS treatment, animal models offer the 
opportunity for in-depth analysis of disease processes. Experimental autoimmune 
encephalomyelitis (EAE) is the most commonly studied mouse model of MS [26]. Here, 
EAE can be actively induced by immunization with myelin peptides, such as MOG35-55, in 
complete Freund’s adjuvant (CFA) and two additional injections of pertussis toxin [27]. 
However, active EAE has certain limitations and is often insufficient to investigate the 
highly dynamic nature of pathogenic immune cells during trafficking, recruitment and 
infiltration of the CNS. Several key aspects of the model have to be considered when 
translating EAE results to MS: first of all, the harsh and strong activation stimulus using 
myelin peptides together with potent adjuvant represents a highly artificial situation for 
activation of autoreactive T cells and thus is not suitable for studying the very early 
activation events in the natural development of disease. Second, most mouse strains 
including C57BL/6 mice (BL6) show a monophasic disease course, but no relapses and 
therefore poorly reflect human disease. Third, most EAE models show focused 
inflammation in the spinal cord, whereas MS is usually dominated by brain inflammation. 
Also, due to the immunization regimen, T cell responses are heavily biased towards CD4+ 
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T cells in EAE, whereas CD8+ T cell responses play a significant role in MS. The earlier 
viewpoint that B cells are not required for EAE was supported by work in mice lacking B 
cells. Disease induced in B cell-deficient C57BL/6 mice immunized with rodent MOG35-55 is 
indistinguishable from disease in WT mice, indicating that T cell responses to this Ag are 
sufficient to induce CNS inflammation and demyelination in this model [28, 29]. However, 
immunization with MOG peptide and CFA bypasses antigen processing and presentation 
by B cells and thus, the active EAE model cannot properly reflect the importance of B cells 
in pathogenic processes. 
1.2.2 Spontaneous EAE mouse models 
To overcome some of these limitations, mouse models with spontaneous EAE 
development can be studied exhibiting an etiopathology that is more comparable to 
human disease. During the past years, two spontaneous EAE mouse models were 
developed. One model on BL6 background combines 2D2 mice, expressing a transgenic 
MOG35-55 peptide-specific TCR, with IgHMOG (TH) mice, expressing a BCR derived from a 
rearranged heavy chain of a MOG-specific antibody [30, 31]. About 60% of 2D2xTH double 
transgenic mice develop spontaneous EAE around 6 weeks of age. The observed 
pathology is similar to NMO, characterized by the presence of inflammatory foci restricted 
to the spinal cord and optic nerve [32, 33]. Therefore, the model was also named 
opticospinal EAE (OSE) mice. The other mouse model is on the SJL/J background: TCR1640 
mice or relapsing-remitting (RR) mice, feature T cells with a transgenic TCR recognizing 
the MOG92-106 peptide. These T cells recruit MOG-specific B cells from the endogenous 
immune repertoire. Spontaneous EAE develops within two to three months of age, with 
an incidence of over 80 % and the majority of mice show a relapsing-remitting (RR) disease 
course. Thus, TCR1640 mice represent the first spontaneous RR animal model for the most 
common form of MS in the Western Society [34]. Both spontaneous EAE models develop 
B cell-dependent disease and offer special advantages over actively induced EAE models 
due to the less artificial disease induction and the closer resemblance of the human 
disease. These models allow us to characterize the role of B cells in initiating events in 
spontaneous EAE, which will provide insight into the pathogenesis of MS. 
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1.3 Insights in MS disease triggers  
1.3.1 T cells in MS and EAE 
Both in MS and EAE, T cells play the most important role in the disease development. 
Demyelination is a key feature in the pathology of MS and therefore myelin protein-
derived antigens have been hypothesized to be the main autoreactive targets. The myelin 
sheath is a greatly extended and modified plasma membrane wrapped around the nerve 
axon in a spiral fashion and functions as an electrical insulator. It consists of lipids and 
contains many different proteins. In patients with MS, but also in healthy individuals, 
myelin proteins like MOG, proteolipid protein (PLP) and myelin basic protein (MBP) have 
been demonstrated to be recognized by circulating CD4+ T cells [35]. Some EAE studies 
implicate the reactivation of infiltrating CD4+ T cells in the CNS by CD11c+ dendritic cells 
(DCs) with the resulting inflammatory response leading to monocyte recruitment, as well 
as naive CD4+ T cell activation that further fuels inflammation [36]. Pesic et al. showed 
that infiltrating T cells interact with macrophage-like cells rather than DCs, as reported 
previously [37, 38]. 
The main CD4+ T cell subsets implicated in disease are Th1 and Th17 cells, and in the 
mouse both subsets can induce disease independently of each other [39]. However, in MS 
conflicting studies report the predominance of one cell type over the other at initial 
diagnosis and during subsequent relapses [40, 41]. Compared with controls, in MS 
patients myelin-reactive peripheral CD4+ T cells expressing the CC-chemokine receptor 6 
(CCR6) show increased expression of Th1 and Th17 cell signature cytokines IFN-y and IL-
17A [42], indicating that both subsets may contribute to the inflammatory processes. 
Additionally, lesional CD4+ T cells have an intermediate phenotype expressing IFN-y and 
IL-17A simultaneously [43], a phenomenon that has also been observed in the mouse and 
may stem from the substantial plasticity of Th17 cells. Despite these evidences, 
ustekinumab, an antibody which targets both IL-12 and IL-23 which are crucial for Th1 and 
Th17 cell differentiation, failed in a Phase II clinical trial in patients with relapsing-
remitting MS [44]. There are several hypotheses for the lack of therapeutic efficacy of this 
antibody. The therapeutic efficacy of ustekinumab might depend on the disease stages. 
In the EAE model, this antibody was shown to be more effective in the prevention regimen 
than the therapeutic treatment for established disease [45]. Thus, IL-12/IL-23 might be 
most important for differentiation and expansion of pathogenic T cells before clinical 
onset of disease. Additionally, the blood–brain barrier (BBB) might be insufficiently 
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disrupted in MS compared to EAE and thus, with an approximate molecular weight of 150 
kDa, ustekinumab might not have crossed the BBB. 
In contrast to EAE, in MS CD8+ T cells are found in higher frequencies in white matter and 
in grey matter cortical lesions than CD4+ T cells [3]. CD8+ T cells predominate in active MS 
lesions, and analyses of their TCR repertoire indicate local expansion of the infiltrated cells 
[46, 47]. These data suggest an active role of CD8+ T cells in the formation of MS lesions. 
Unfortunately, in the vast majority of EAE models the disease is mediated by CD4+ T cells, 
while CD8+ T cells are found only in very low frequency in the CNS infiltrates. Thus, their 
role is difficult to study and poorly understood.   
1.3.2 B cells in MS and EAE 
In comparison to T cells, infiltrating B cells in the CNS vary in numbers, localisation and 
pathology throughout disease progression depending on stage and type of MS [48-50]. 
Clonally expanded B cells can be found in the meninges, and in the perivascular space, but 
also in parenchyma and CSF. Intrathecal B cells produce antibodies detectable in CSF as 
oligoclonal bands (OCBs) and to date OCBs are a prominent immundiagnostic criterion 
[50]. Plasma cells, which are the main antibody producers, are increased with age in 
patients with primary and secondary progressive MS [3]. Some patients with secondary 
progressive MS have aggregates of plasma cells, B cells, T cells and FDCs in the meninges, 
also called tertiary lymphoid structures which may be a product of long term inflammation 
[51]. In contrast, meningeal infiltration is diffuse and without structures in primary 
progressive MS [52].  
B cells have several functions through which they could contribute to the pathology of 
MS. One important function of B cells is their ability to present antigens to T cells in 
context of major histocompatibility complex class II (MHC II) [53]. If they are specific for 
the same antigen as the interacting T cell, B cells are 10.000 fold more potent in antigen 
presentation than DCs, and they are especially effective in presenting low concentrations 
of antigen [34, 54]. Moreover, B cells can differentiate into antibody-secreting plasma 
cells that cause tissue damage either via complement activation or antibody-dependent 
cell-mediated toxicity. Long lived plasma cells produce IgG antibodies which lead to Fc 
receptor activation on macrophages and DCs, inducing production of cytokines, which 
attract and activate other immune cells and cause further tissue injury [53]. 
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In most MS patients, the autoantigen is unknown which makes treatment more difficult.  
The most prominent autoantigens in MS are MOG, neurofascin, contactin and the ATP-
dependent inwardly rectifying potassium channel KIR4.1 [55-58]. However, only a fraction 
of patients shows detectable reactivity against one or several of these antigens. A 
promising approach for the identification of antigens recognized by antibodies that form 
oligoclonal bands is to produce recombinant immunoglobulin from B cells or plasma cells 
that are clonally expanded in CSF [59, 60]. Brändle and colleagues produced six 
recombinant antibodies from four MS patients and identified three different 
autoantigens. All of them are conformational epitopes of ubiquitous intracellular proteins 
not specific to brain tissue. These findings indicate that the B cell response in MS is 
heterogeneous and partly directed against intracellular autoantigens released during 
tissue destruction [61]. Another group tried to produce recombinant antibodies from B 
cell clones from MS CSF in human tissue culture but failed to find immunoreactivity to 
myelin antigens [59, 60]. These studies demonstrate, that it is still difficult to find target 
antigens or even potential markers to identify onset of disease development.  
Activated B cells can produce pro- and anti-inflammatory cytokines to activate and 
differentiate T cells and macrophages or block their activation. Pro-inflammatory B cell 
cytokines include IL-6, IL-12, Granulocyte macrophage - colony stimulating factor (GM-
CSF), TNF and lymphotoxin (LT), which modulate T cell differentiation, migration of DCs, 
activation of macrophages and provide feedback stimulatory signals for further B cell 
activation. Several studies show an increase of B cells in MS patients producing 
proinflammatory cytokines [62-64]. Anti-inflammatory B cell cytokines like IL-10 can 
inhibit T cell or macrophage activation. Recently, a B cell subset that can produce IL-10 
and resembles mouse regulatory B cells has been identified in humans [65].  
The importance and differential roles of B cells for the development of EAE was shown by 
depletion experiments. B cells can be efficiently depleted by antibodies targeting the 
surface marker CD20. While anti-CD20-mediated B cell depletion before the induction of 
active EAE exacerbated disease symptoms, depletion of B cells during disease progression 
profoundly suppressed symptoms. The increased severity of EAE with early B cell 
depletion resulted from an increased influx of encephalitogenic T cells into the CNS, due 
to the depletion of the rare IL-10-secreting CD1dhi/CD5+ regulatory B cell subset. During 
late depletion, B cells that promoted continuous generation of autoantigen-specific CD4+ 
T cells and sustained entry of encephalitogenic T cells into the CNS were removed from 
the system [66]. Thus, B cells can have dual functions: either in driving autoimmunity as 
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APCs, by producing autoantibodies, or by secreting inflammatory cytokines, such as IFN-γ 
and IL-6; or in suppressing autoimmunity as IL-10 producing regulatory B cells, dampening 
the inflammatory potential of effector T cells or modulating the activity of other 
surrounding APCs [67]. 
Antigen presentation by B cells is of particular importance for the T – B cell crosstalk 
observed in the spontaneous EAE models mentioned before. IgHMOG B cells in the OSE 
mouse model can concentrate MOG with their antigen-specific BCR, and efficiently 
present it to MOG-reactive T cells. This results in mutual activation, proliferation, and 
differentiation, and B cells of those mice switch their isotype and produce high titers of 
MOG-specific IgG1 autoantibodies, while T cells in the CNS secrete more IFN-γ and IL-17 
than single-transgenic controls [32]. In the TCR1640 (RR) mouse model, MOG-specific B cells 
from the endogenous repertoire are recruited by MOG-reactive transgenic T cells and are 
driven into germinal center reactions, leading to the appearance of spontaneous anti-
MOG autoantibodies in the serum of these mice [34, 68]. In addition to T cells, in the RR 
model B cells infiltrate into the CNS parenchyma, too. Deposits of antibodies along with 
some activated complement can be found in demyelinated lesions of diseased RR mice. 
The recruitment of MOG-specific B cells is strictly dependent on the presence of the target 
antigen, since TCR1640 mice deficient for MOG do not develop RR-EAE nor show any 
corresponding autoantibodies [34]. In addition, early infiltration of T and B cells into the 
CNS of RR mice could already be found at pre-clinical stages at an age of four weeks, and 
anti-MOG autoantibodies were present in the serum at around five weeks after birth. 
Active germinal centers were found in cervical lymph nodes of RR mice, and MOG-specific 
B cells (IgHMOG) preferentially migrated to GCs in cervical lymph nodes but not to other 
lymphoid organs [68]. This could be due to myelin debris draining from the subclinically 
inflamed CNS or being transported by phagocytes to cervical lymph nodes. This would 
induce further activation of MOG-specific T cells, which then in turn drive MOG-specific B 
cells into germinal center reactions, resulting in a full attack on the target organ by 
autoreactive T cells along with the emergence of isotype class switched autoantibodies 
[69]. 
In summary, B cells have multifunctional immunmodulatory effects in pathogenesis of MS 
suggesting that modulation of specific B cell functions may be an interesting therapeutic 
target. Currently, several therapies affect B cell immunology. Phase II clinical trials with 
the CD20-specific monoclonal antibodies rituximab or ocrelizumab have shown great 
efficacy of B cell depletion therapy to reduce relapse rates in patients with relapsing-
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remitting MS [70, 71]. These drugs deplete the majority of B cell subsets but not plasma 
cells indicating that the role of B cells as antigen presenting cells and cytokine producers 
may be more important in disease development and progression than their role as 
antibody producers. 
1.3.3 Antigen transport and priming of autoreactive lymphocytes in MS and 
EAE 
Auto-antigen presentation followed by activation of autoreactive B and T cells is a crucial 
event in the development of EAE and MS. There are several potential locations where 
autoreactive B and T cells could find their antigen. One option is that autoreactive B and 
T cells find antigens directly in the CNS, meaning there is initially no antigen transport to 
regional lymph nodes or only after inflammation has started, causing the BBB to become 
leaky. Another option is that antigens are transported to regional lymph nodes - either in 
soluble form, via APCs or exosomes - and activate B and T cells there, which then migrate 
to the CNS in search of antigen. In another scenario, activation of autoreactive immune 
cells could take place in the instestine via molecular mimicry or bystander activation 
(Figure 1) followed by migration to the target organ. 
A current theory is that APCs or soluble auto-antigens can migrate from the CNS to 
regional lymph nodes and initiate an autoimmune response [72]. Lymph nodes close to 
the CNS include superficial CLNs (sCLN), and deep CLNs (dCLN). Cells and antigens from 
the brain could reach CLNs either by entering the nasal lymphatics via the drainage 
channels leading from the subarachnoid space inferior to the olfactory bulbs to the 
cribriform plate. Alternatively, they can enter blood vessels through the arachnoid villi of 
the venous sinuses [73]. Previous studies with rats showed that radioiodinated serum 
albumin injected into brain and cerebrospinal fluid (CSF) drains to CLNs [74]. Furthermore, 
monocytes and dendritic cells (DCs) are able to migrate from CSF to CLNs when injected 
[73, 75]. In addition to these drainage pathways, Louveau et al. recently discovered 
lymphatic vessels lining dural sinuses, which express all molecular hallmarks of lymphatic 
endothelial cells, are able to drain immune cells from CSF, and are conncected to dCLNs 
[76]. However, if cells and auto-antigens also migrate from the CNS to CLNs in EAE and 
MS, and whether that could be an important mechanism for the induction of disease is 
still not fully understood.  
Immune reactions in CLNs have been suggested to play a significant role in EAE 
development. Phillips and colleagues demonstrated that the removal of CLNs decreases 
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the lesion number in the brain in a cryolesion-induced cerebral EAE model in rats by 40 % 
[77]. In addition, surgical removal of CLNs and lumbar lymph nodes in acute, chronic, and 
chronic-relapsing EAE reduced disease in all models, most strikingly in chronic-relapsing 
EAE [78]. Furthermore, in human brain-derived antigens can be found in CLNs after stroke 
[79] indicating a specific drainage pathway. The auto-antigen MBP, neural lipids and PLP 
are present in the CLNs of marmoset monkeys with MOG-induced EAE and patients with 
MS [80, 81]. Moreover, neuronal antigens like microtubule-associated protein 2 (MAP-2), 
neuron specific enolase (NSE) and neurofilament (NF-H) were found in CLNs of MS 
patients [80]. Collectively, these studies support the hypothesis that antigen-specific 
immune responses in CLNs are important for initiating disease. However, when, how and 
along which pathway myelin proteins are transported from the brain into the CLNs has 
not been clearly demonstrated yet. 
One mechanism how CNS auto-antigens could be transported in EAE and MS is by 
exosome formation. Exosomes are small membrane vesicles of about 150 nm in size, 
generated by the endosomal system and released directly from the plasma membrane or 
upon fusion of multivesicular bodies (MVBs) with the plasma membrane [82]. Immune 
cells like dendritic cells and B cells, but also non-immune cells, including astrocytes and 
oligodendrocytes, are able to secrete exosomes. Consequently, body fluids like serum, 
urine and CSF contain high amounts of microvesicles [83]. Exosomes can carry cell-type 
specific components such as integrins, tetraspanins (CD9, CD63), proteins involved in MVB 
biogenesis (Alix, Tsg101), but also mRNAs and miRNAs which can alter protein expression 
[84, 85]. Importantly, exosomes are able to migrate between cells, and could thus act as 
a transportation system for different antigens like MBP, PLP, and MOG [86, 87]. Possibly, 
exosomes could indirectly trigger an autoimmune T cell response after being taken up and 
thus delivering the autoantigen to APCs such as DCs or macrophages, which in turn 
present the autoantigens on their surface to activate T cells [87]. In addition, several 
studies have shown that exosomes can also directly present antigen in complex with MHC 
class II to T cells and modulate immune functions [82, 88, 89]. For example, insulinoma-
released exosomes in the non-obese diabetic (NOD) mouse model can activate 
autoreactive T cells and may cause insulinitis [86]. Taken together, studies for the possible 
involvement of exosomes in transport of autoantigens are highly relevant. 
APCs and exosomes may present autoantigens to activate autoreactive B and T cells. 
However, also peptides/epitopes from microbes could potentially cross-activate 
autoreactive T or B cells due to sequence similarities between “self” and pathogen-
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derived peptides/epitopes, a phenomenon which is called molecular mimicry [90]. 
Furthermore, it has been shown that autoreactive T cells are activated de novo by self 
epitopes released secondary to pathogen-specific T cell-mediated bystander damage [91].  
Humans carry 3.8·1013 microorganisms, a value of about 1:1 to the total number of human 
cells in the body [92]. These microorganisms live in symbiosis with their hosts contributing 
to the digestion and fermentation of carbohydrates, and production of vitamins. In 
addition, they also protect the host from colonization with pathogenic microbes and 
shape the hosts immune system [93-95]. Thus, the microbiota is important for the 
development of gut-associated lymphoid tissues (GALTs) and responsible for Peyer’s 
Patch size and organization in germ-free mice compared to colonized controls [96]. On 
the other hand, the host’s innate immune system also shapes the intestinal ecosystem. 
As a consequence, complex interactions between the microbiota and the host immune 
system are essential for gut homeostasis [93]. Environmental factors like diet and lifestyle 
can disturb the balance of the microbiota [97], and an imbalance can affect the host 
immune system and disease [98]. For instance, it has recently been shown that 
rheumatoid arthritis and type I diabetes are linked to an altered composition of gut 
microbiota [99, 100]. First studies also hint towards an important role of the microbiota 
in EAE development. The early events that lead to the development of MS as well as EAE 
are not well understood. Accumulating evidence indicates that composition of 
commensal microbiota could be relevant for the induction of autoimmunity [101]. Thus, 
it has been shown that oral treatment with antibiotics reduces the symptoms of EAE and 
induces a protective population of CD5+ B cells [102, 103]. Furthermore, relapsing-
remitting (RR) mice are fully protected from spontaneous EAE, when housed under germ-
free conditions, suggesting that the microbiota contribute somehow to the generation of 
a pathogenic autoimmune response in this model [68]. Additionally, microbiota derived 
from MS patients in a twin study (one twin healthy, the other has MS) gavaged to RR mice 
triggered a higher spontaneous EAE incidence than the microbiota derived from the 
healthy twin [104]. The colonized mice had different microbial profiles and recipients of 
MS-twin samples produced less IL-10 indicating an immunmodulatory effect of microbiota 
in MS disease. These findings prompted us to hypothesize that auto-reactive B and T cells 
may initially be activated in the gut either by bystander activation or via molecular 
mimicry by microbial antigens and consequently migrate to the CLNs and/or the CNS to 
promote the development of EAE. 
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Figure 1: Potential locations for activation of autoreactive B cells in the RR mouse model 
In RR mice MOG-specific B cells are recruited from the endogenous immune repertoire. When and where B 
cells become activated is still unknown. Possible autoreactive B cell activation sites could be CNS (1), CLNs (2) 
or the gut (3). (1) In CNS, B cells could be activated through antigen presentation. (2) Antigens could be 
alternatively transported to CLN via APCs, exosomes, or in soluble form. (3) Furthermore, B cells could be 
activated in the gut by molecular mimicry or bystander activation (created by Bettina Martin). 
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OBJECTIVE 
In the RR mouse model, T cells recruit MOG-specific B cells from the endogenous immune 
repertoire and EAE develops spontaneously in a B cell-dependent manner within two to three 
months of age with a relapsing-remitting (RR) disease course. Thus, the RR mouse represents 
an excellent animal model for the most common form of MS. This model raises general 
questions regarding when and where autoreactive B cells become activated during EAE and 
MS, and which effector functions and molecular mechanisms contribute to B cell 
pathogenicity.  
Regarding the site of activation there are several options in the RR mouse model, which may 
also be relevant in other EAE models as well as in MS: first, B cells could be activated directly 
in the CNS, migrate to regional lymph nodes and undergo proliferation and differentiation. 
Second, antigens from the CNS may be transported to regional lymph nodes where they 
activate B cells, which then undergo proliferation and differentiation. Or third, B cells are 
activated in the periphery, possibly the intestine, and then recruited to CNS related lymph 
nodes. Therefore, one objective of the present study was to examine antigen transport and 
priming of autoreactive lymphocytes in spontaneous EAE. Firstly, transport and presence of 
myelin antigens in peripheral CLNs in RR mice was investigated with several methods, as well 
as exosomes as a potential transportation system for myelin antigens and their involvement 
in initiating MOG-specific T and B cell responses in EAE. Secondly, activation of autoreactive 
B cells in the gut as the site of initial priming via molecular mimicry or bystander activation 
was studied with secondary recruitment to CLNs during development of spontaneous EAE.  
Regarding pathogenic B cell effector functions and properties in EAE and MS, several aspects 
have to be considered including production of pathogenic antibodies, presentation of 
autoantigen to autoreactive T cells and production of cytokines. However, functional studies 
have so far been hampered by limited possibilities to expand, differentiate and manipulate 
B cells in vitro. Thus, the second objective of this study was to establish a new cell culture 
system for B cell expansion, differentiation and specific selection to overcome current 
limitations to study autoreactive B cells. With this new tool it is now possible to study origin, 
migration and repertoire of auto-reactive B cells from RR mice and to study/manipulate 
pathogenic properties of auto-reactive B cells in EAE.
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2 MATERIAL AND METHODS 
2.1 Material 
2.1.1 Animals 
All animals used in this study were bred in the animal facilities of the Max-Planck-Institutes 
of Biochemistry and Neurobiology. The animal procedures were in accordance with 
guidelines of the committee on animals of the Max-Planck-Institute of Neurobiology, and 
with the licenses of the Regierung von Oberbayern. 
2D2 mice 
MOG-specific TCR transgenic mouse on the C57Bl/6 background: CD4+ T cells express a 
transgenic TCR recognizing MOG35-55 peptide in the context of I-Ab [30].  
Actin GFP mice 
Transgenic strain carrying the Green Fluorescent Protein (GFP) under the control of the 
chicken beta-actin promoter and human cytomegalovirus (CMV) intermediate early 
enhancer. The transgene was found on the X chromosome [105]. 
H2M mice 
For the generation of transgenic MOG over expressing mice (H2M), the entire coding region 
of murine MOG from mouse brain cDNA was amplified by RT-PCR using the primers SaMOG: 
5´-ACGCGTCGACCTCAGCTTGGCCTGACCC-3´ and BgMOG: 5´-CGAAGATCTGCTGGGCTCTCCTT-
CCGC-3´ which bear the restriction sites Sal I and Bgl II, respectively. The amplified cDNA was 
inserted into the sites Sal I and Bgl II of the vector pHSE3´ containing H2-Kb promoter and 
immunoglobulin heavy chain enhancer for transgenic expression. The transgenic mouse was 
obtained by pronuclear microinjection of a purified Xho I DNA fragment into C57BL/6 oocytes 
and a founder mouse that expressed the transgene was bred with C57BL/6 mice [106]. 
HEL mice 
SWHEL mice carry B cells with a hen egg lysozyme (HEL)-specific heavy chain and light chain 
genes in knock-in and transgenic configurations [107] resulting in HEL-specific B cells that are 
still able to switch isotype.  
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PLP-eGFP mice 
EGFP was fused to 3’UTR of the PLP promoter. Three founder lines were selected (EGFP3, 
EGFP5 and EGFP10) and bred homozygously. It was shown previously that transgene 
expression of EGFP together with PLP is consistent in all stages of oligodendrocyte 
differentiation. Mice were provided by Prof. Dr. Martin Kerschensteiner [108]. 
R&D mice 
R&D mice were created by Marsilius Mues. The R&D mouse is a valuable tool to study B cell 
functions in EAE since B cells express red fluorescent protein (RFP) for in vivo tracking, and 
the human Diphtheria toxin receptor (DTR), which allows for depletion of B cells at any given 
timepoint via administration of diphtheria toxin [109]. A tandem dimer RFP (tdRFP) was 
chosen that is suitable for sustained and high expression in murine lymphocytes. TdRFP 
consists of two monomeric RFPs interlinked by a flexible linker. For simultaneous expression 
of tdRFP and DTR (termed R&D), both genes were placed in succession, separated by an 
internal ribosomal entry site (IRES), and subcloned into the cytomegalovirus (CMV) 
promoter-driven expression vector pCMV to obtain pCMV-R&D. 
RR mice 
TCR1640 mice feature T cells with a transgenic TCR recognizing the MOG92-106 peptide in the 
context of I-Aq on the SJL/J background [34]. 
TH mice 
This mouse model expresses a BCR, derived from a rearranged heavy chain of a MOG-specific 
antibody [31, 32]. The mouse was generated as a knock-in mutant, in which the VDJ region 
of the MOG-specific H chain from the hybridoma 8.18-C5 was inserted into the natural 
location of rearranged V genes in the H gene locus. MAb 8.18-C5 mediates demyelination 
both in vitro and in vivo [110, 111] and exacerbates clinical disease in EAE [112]. In mature 
mutant mice the transgenic Ig H chain is expressed in almost all B cells, resulting in a high 
frequency of MOG-specific B cells (80-90 %) and high levels of MOG-specific Ig in the serum. 
Importantly, TH B cells can undergo normal isotype switching and – due to the endogenous 
pool of light chains – a certain degree of affinity maturation. 
2.1.2 Antibodies  
ELISA antibodies were purified or biotinylated and used in conjunction with streptavidin 
coupled with HRP. 
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Table 1: Capture antibodies and proteins for Ig-ELISA 
Specificity Label Clone  Host/Isotype Dilution 
Company 
(Catalog Number) 
Rat α-m IgM Purified II/41  Rat IgG2a, κ 1:500 
BD Biosciences 
(553435) 
Rat α-m IgG1 Purified A85-3  Rat IgG1, κ 1:500 
BD Biosciences 
(553445) 
rMOG Purified -  
Produced in 
bacteria 
10 
µg/ml 
In house 
Table 2: Standard antibodies for Ig-ELISA 
Specificity Label Clone Host/Isotype Dilution 
Company 
(Catalog Number) 
Mouse IgM i.c Purified G155-228 BALB/c IgM, κ 1:500 BD Biosciences (553472) 
Mouse IgG1 i.c. Purified 107.3 BALB/c IgG1, κ 1:500 BD Biosciences (553447) 
MOG (8.18c5) Purified 8.18c5 Mouse mIgG1a 1 µg/ml In house produced [113] 
Table 3: Detection antibodies for Ig-ELISA 
Specificity Label Clone Host/Isotype Dilution 
Company 
(Catalog Number) 
Rat α-m IgM Biotin R6-60.2 LOU/M IgG2a, κ 1:1000 BD Biosciences (553406) 
Rat α-m IgG1 Biotin A-85 LOU/M IgG1, κ 1:1000 BD Biosciences (553406) 
Mouse IgG1 [a] Biotin 10.9 SJL IgG2a, κ 1:1000 BD Biosciences (553500) 
Mouse IgM [a] Biotin DS-1 C57BL/6 IgG1, κ 1:1000 BD Biosciences (553515) 
Streptavidin HRP - - 1:2000 
BD Biosciences 
 (18-4100-51) 
Flow cytometry antibodies were labeled with eFluor450, FITC, PE, PerCP, PE-Cy7, APC, APC-
Cy7, BV 605, Alexa Fluor 647, or were biotinylated and used in conjunction with streptavidin 
coupled fluorophores. 
Table 4: Primary antibodies and reagents for FACS 
Specificity Label Clone Host/Isotype Dilution 
Company 
(Catalog Number) 
7AAD PerCP - Viability dye 
3 
µl/well 
BioLegend (420404) 
B220 (CD45R) PerCP RA3-6B2 Rat IgG1, κ 1:200 Pharmigen (01125B) 
BAFF FITC Buffy-2 Rat IgM 1:100 Abcam (ab16082) 
CD4 
PerCP      
BV605 
RM4-5 Rat IgG2a, κ 1:200 
BD Biosciences (45-0042-82) 
BioLegend (100547) 
CD9 APC M-L13 Rat IgG2a, κ 1:200 Becton Dickinson (341648) 
CD11b PE-Cy7 M1/70 Rat IgG2b, κ 1:200 BioLegend (101215) 
CD11c BV 605 N418 Ar Ham IgG 1:200 BioLegend (117334) 
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CD19 
FITC          
PerCP              
eFluor450 
1D3 Rat IgG2a, κ 1:200 
Pharmigen (553785)  
BD Biosciences  
(45-0193-82) BD Biosciences 
(48-0193-82) 
CD38 eFluor 450 - Rat IgG2a, κ 1:200 
BD Biosciences  
(48-0381-82) 
CD40L 
(CD154) 
PE MR1 Ar Ham IgG3, κ 1:200 Pharmigen (553658) 
CD45 eFluor 450 30-F11 Rat IgG2b, κ 1:200 
BD Biosciences 
 (48-0451-80) 
CD45.1 FITC A20 
Mouse IgG2a, 
κ 
1:200 
BD Biosciences 
 (11-0453-82) 
CD45.2 APC 104 
Mouse IgG2a, 
κ 
1:200 
BD Biosciences  
(17-0454-81) 
CD63 PE NVG-2 Rat IgG2a, κ 1:200 
BioLegend 
 (143903) 
CD80 PE 16-10A1 Ar Ham IgG 1:200 BioLegend (104707) 
CD86 Biotin GL1 Rat IgG2a, κ 1:200 
BD Biosciences 
 (13-0862-82) 
CD90.2 Biotin 30-H12 Rat IgG2a, κ 1:200 
BD Biosciences 
 (13-0903-82) 
CD95 (Fas) PE-Cy7 Jo2 Ar Ham IgG2 1:200 Pharmigen (557653) 
CD95L (FasL) PE MR1 Mouse IgG 1:200 
BD Biosciences 
 (12-1541-82) 
CD138 
PE                 
APC 
281-2 Rat IgG2a, κ 1:200 
Pharmigen (553713)         
Pharmigen (558626) 
GL7 
Alexa Fluor 
647 
GL7 Rat IgM 1:200 
BD Biosciences  
(50-5902-82) 
H-2kb (MHCI) FITC 
AF6-
88.5.5.3 
Mouse IgG2a, 
κ 
1:200 
BD Biosciences 
 (11-5958-80) 
H-2kd (MHCI) PerCP SF1-1.1 
Mouse IgG2a, 
κ 
1:200 BioLegend (116618) 
HEL Biotin - - 1:100 Sigma (L6876) 
IgA PE 11-44-2 Rat IgG1, κ 1:200 
BD Biosciences  
(12-5994-82) 
IgD FITC 11-26c.2a Rat IgG2a, κ 1:200 Pharmigen (553439) 
IgE PE RME-1 Rat IgG1, κ 1:200 BioLegend (406907) 
IgG1 BV 605 A85-1 Rat IgG2a, κ 1:200 BD Horzon (563285) 
IgG2a/b FITC R2-40 Rat IgG1, κ 1:200 Pharmigen (553399) 
IgM PE-Cy7 Il/41 Rat IgG2a, κ 1:200 
BD Biosciences  
(25-5790-82) 
IgMa PE DS-1 
C57BL/6 IgG1, 
κ 
1:200 BD Bioscience (553517) 
mMOG FITC - 
Produced in 
HEK cells 
1:100 In house produced [114] 
MOG (8.18c5) Purified 8.18c5 
Mouse 
mIgG1a 
1:200 In house produced [113] 
MOG (Z2) FITC Z2 
Mouse 
mIgG1a 
1:100 In house produced [115] 
MOGtet FITC, PE - - 1:100 In house produced [114] 
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PNA Biotin - - 1:200 Vector (B-1075) 
Vα3.2 APC RR3-16 Rat IgG2b, κ 1:200 BD Biosciences (553218) 
Vα8.3 PE B21.14 Rat IgG2b, κ 1:200 
BD Biosciences 
 (12-5803-82) 
Vβ4 FITC KT4 Rat IgG2b, κ 1:200 BD Biosciences (553365) 
Vβ11 PE RR3-15 Rat IgG2b, κ 1:200 BD Biosciences (553198) 
Table 5: Secondary antibodies and reagents for FACS 
Specificity/Anion Label Clone Host/Isotype Dilution 
Company 
(Catalog Number) 
Azide 
Alexa Fluor 
647 
- -  Thermo Fisher (A10277) 
Streptavidin 
PE               
APC-Cy7 
- - 1:1000 
Pharmigen (554061)             
BD Biosciences  
(47-4317-82) 
IHC antibodies were labeled with Alexa Fluor 488, 568 or 647, or were biotinylated and used 
in conjunction with streptavidin coupled fluorophores. 
Table 6: Primary antibodies for IHC 
Specificity Label Clone Host/Isotype Dilution 
Company 
(Catalog Number) 
B220 
Purified              
Biotin 
RA3-6B2 Rat IgG2a, κ 1:200 
Pharmingen (550286) 
Pharmigen (553085) 
CD4 Alexa Fluor 647 RM4-5 Rat IgG2a, κ 1:200 BioLegend (100530) 
CD11b AlexaFluor 647 M1/70 Rat IgG2a, κ 1:200 BioLegend (101220) 
CD68 Alexa Fluor 647 ED1 Mouse IgG1 1:20 Biorad (MCA341A647) 
MBP Purified Polyclonal Rabbit IgG 1:200 Abcam (ab40390) 
MOG 
 (8.18-C5) 
Biotin 8.18-C5 Mouse IgG1 1:200 In house hybridoma 
MOG (Z2) Biotin Z2 Mouse IgG2a 1:500 In house hybridoma 
MOG Fab2 Biotin Z2 Mouse IgG2a 1:200 In house hybridoma 
Mouse IgG1 Biotin A85-1 Mouse IgG1 1:200 Pharmigen (553441) 
PLP Purified Polyclonal Rabbit IgG 1:200 Abcam (ab28486) 
Rabbit IgG Purified - Rabbit IgG 1:200 Dako (Z025902-2) 
Rat IgG2a Purified DD13 Rat IgG2a, κ 1:200 Millipore (CBL605) 
Table 7: Secondary antibodies and reagents for IHC 
Specificity Label Clone Host/Isotype Dilution 
Company 
(Catalog Number) 
Rat IgG Alexa Fluor 488 Polyclonal Goat IgG 1:1000 Invitrogen (A-11006) 
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Rat IgG Alexa Fluor 568 Polyclonal Goat IgG 1:1000 Invitrogen (A-11077) 
Rabbit IgG Alexa Fluor 488 Polyclonal Goat IgG 1:1000 Abcam (ab150077) 
Streptavidin Alexa Fluor 488 - - 1:1000 Invitrogen (ab150077) 
Streptavidin Alexa Fluor 568 - - 1:1000 Invitrogen (S-11226) 
Western Blot antibodies were purified and used in conjunction with anti-species IgG 
secondary antibody coupled with HRP. 
Table 8: Primary antibodies for Western Blot 
Specificity Label Clone Host/Isotype Dilution 
Company 
(Catalog Number) 
Alix Purified 49/AIP1 Mouse IgG1 1:300 BD Biosciences (611620) 
Calnexin Purified 3H4A7 Mouse IgG2b 1:1000 Santa Cruz (sc-130059) 
MOG (8.18-C5) Purified 8.18-C5 Mouse IgG1 1:500 In house hybridoma 
Tsg101 Purified C-2 Mouse IgG2a 1:500 Santa Cruz (sc-7964) 
Table 9: Secondary antibodies for Western Blot 
Specificity Label Clone Host/Isotype Dilution 
Company 
(Catalog Number) 
Goat IgG HRP - Donkey 1:2000 Santa Cruz (sc-2020) 
Mouse IgG HRP - - 1:2000 Cell signaling (7076S) 
Rabbit IgG HRP - - 1:2000 Santa Cruz (sc-32906) 
2.1.3 Buffers and solutions 
Buffers for ELISA 
Phosphate Buffered Saline (PBS) 
137 mM NaCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
2.7 mM KCl 
Add ddH2O, pH to 7.2 with HCl 
Washing solution 
0.05% (v/v) of Tween-20 in PBS 
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Blocking solution 
10% (v/v) fetal bovine serum in PBS 
TMB Substrate and Stop solution 
TMB Substrate Set (A and B) – BioLegend (421101), store at 4°C 
TMB Stop solution – BioLegend (423001), store at RT 
 
Buffers for FACS 
FACS staining buffer 
1% (w/v) BSA, 0.1% (w/v) sodium azide in PBS 
Intracellular cytokine staining buffer 
FACS buffer + 0.1% Saponin or Fixation and Permeabilization Buffer KIT (eBioscience, 00-
5523-00) 
 
Buffers for Immunohistochemistry 
Blocking solution 
4% (w/v) BSA+ 4% (v/v) goat serum in PBS 
Staining and washing solution 
1% (w/v) BSA + 1% (v/v) goat serum in PBS 
 
Buffers for Western Blot 
Cell lysis buffer (native) 
150 mM NaCl, 20 mM Tris-HCl, 1% (v/v) Triton-X 100 
RIPA buffer 
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton-X 100, 0.5% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS 
Lämmli running buffer 10x 
250 mM Tris-base, pH 8.8, 1% (w/v) SDS, 1.92 M glycine 
Lämmli loading buffer 2x 
200 mM Tris-HCl, pH 6.8, 10% SDS, 10% (v/v) glycerol, 10%-ME, bromophenol blue as needed 
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Anode buffer I 
300 mM Tris, pH 10.4, 20% (v/v) methanol 
Anode buffer II 
25 mM Tris, pH 10.4, 20% (v/v) methanol 
Cathode buffer 
25 mM Tris, pH 9.4, 40 mM 6-aminohexanic acid, 20% (v/v) methanol 
 
Erythrocytes lysis and lymphocyte extraction from CNS and intestine 
 ACK buffer 
150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA 
Percoll (GE Healthcare)  
Stock Isotonic Percoll (SIP): 9 parts (v/v) Percoll + 1 part (v/v) of NaCl 1.5 M (d=1.123)  
Percoll d=1.080: 10 ml SIP + 5.7 ml PBS 
 
Genotyping analysis buffers 
Heparin solution 
200 units heparin (Sigma) in PBS 
Mouse tail digestion buffer 
100 mM Tris-HCl, pH 8.5, 200 mM NaCl, 5 mM EDTA, 1% Tween-20, 1 mg/ml Proteinase K 
TAE running buffer 
40 mM Tris-HCl, 40 mM acetic acid, pH 8.0, 1 mM EDTA 
DNA loading dye 10x 
50 mM Tris-HCl, pH 7.6, 60% (v/v) glycerol, 0.05% (w/v) bromophenol blue, 0.05% (w/v) xylen 
cyanol FF 
2.1.4 Cell culture  
40LB cells 
40LB cells were created in the Kitamura lab [116]. BALB/c 3T3 fibroblast were transfected 
with mouse CD40L cDNA cloned into the expression vector pApuro2. Stable clones were 
selected by puromycin (40L cells). 40L cells were transfected with BAFF cDNA cloned into 
pCA-neo vector and selected with G418 (40LB cells). 
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Bone marrow derived dendritic cells (BMDCs) 
BMDCs were isolated from either C57BL/6 or from H2M mice (2.1.4 and 2.2.1). 
EL4 and EL4 MOG cells 
EL4 cells were originally isolated from a T cell lymphoma induced in a C57BL/6 mouse by 9,10-
dimethyl-1,2-benzanthracene treatment (suspension cells) and are commercially available. 
For EL4-MOG cells, the mouse MOG cDNA was cloned into the retroviral vector pLXSN 
(Clontech Laboratories, Inc.) and transformed into a GP+E-86 packaging cell line. Virus-
containing supernatant was used to stably transduce the mouse EL4 lymphoma cell line [34]. 
FasL cells 
FasL cells were created in the Kitamura lab [29]. 40LB cells were first transduced with pSIREN-
RetroQ-shFas vector and consequently Fas negative cells were further transduced with pMX-
FasLIRES-hCD8 vector. A single clone expressing FasL and hCD8 was obtained by limiting 
dilution assay.   
HEL-40LB cells 
HEL-40LB cells were created in the Kitamura lab [117]. 40LB cells were transduced with the 
pMX-mHEL-IRES-GFP vector, and a single clone expressing mHEL and eGFP, termed 40LB-
mHEL, was selected by limiting dilution. 
MOG-40LB cells and MOG-FasL cells 
Cell lines were created via viral transduction by Anneli Peters. Phoenix cells were transfected 
with pLXSN-MOG and pCLEco and cultured for virus production. Afterwards feeder cells were 
infected with virus-containing supernatant from phoenix cells. Expression of MOG was 
determined by FACS and high expressors were cloned in a limiting dilution assay. 
2.1.5 Media 
Medium for exosome collection 
FCS was either centrifuged at 100,000 rcf 4 °C ON and filtered, or RPMI complemented 
medium was prepared without FCS to remove exosomes from medium, which influences 
exosome analysis and production from other cells. 
Medium for iGB cell culture 
RPMI 1640 (Sigma-Aldrich, Taufkirchen) were complemented with 100 µM MEM non-
essential amino acids, 1 mM sodium pyruvate, 50,000 units penicillin, 50 mg streptomycin, 2 
mM L-glutamine (all Gibco, Karlsruhe), 10mM HEPES (Sigma) and 10% fetal calf serum (FCS) 
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(Lot 094M3277 Sigma). RPMI 1640 medium was further complemented with 550 µM 2-ME. 
Prior to use FCS was inactivated for 1 h at 56°C. Media were sterilized by filtration (pore size 
0.2 µm). All quantities refer to 500 ml of medium. 
 
Medium for intestine preparation 
CMF/Hepes Buffer (500ml) 
10% (v/v) 10 x HBSS 
10 mM Hepes 
Add ddH2O up to 500 ml (For CMF/Hepes/EDTA Buffer add additionally 5 ml EDTA 0.5 M) 
RPMI-10 
10 mM Hepes 
5% (v/v) FCS 
Add ddH2O up to 500 ml 
RPMI and DMEM medium (complemented) 
Media RPMI 1640 and DMEM (both Sigma-Aldrich, Taufkirchen) were complemented with 
100 µM MEM non-essential amino acids, 1 mM sodium pyruvate, 50,000 units penicillin, 50 
mg streptomycin, 2 mM L-glutamine (all Gibco, Karlsruhe), and 10% FCS (Biochrome, Berlin). 
RPMI 1640 medium was further complemented with 200 µM 2-ME. Prior to use FCS was 
inactivated for 1 h at 56°C. Media were sterilized by filtration (pore size 0.2 µm).  
2.1.6 Primers 
Table 10: Primers for qPCR mMOG Exon1-3 
Primer name Gene Oligo sequence (5‘ → 3‘) Label References 
mMOG sense #8 MOG GTGCTGACTCTCATCGCACTTG FAM/TAMRA - 
mMOG AS #9 MOG GCACCCTCAGGAAGTGAGGAT FAM/TAMRA - 
mMOG Probe #10 MOG CGTGCAGAAGTAGAGAATCTCCATCGGAC FAM/TAMRA - 
mMog-Exon 1-sense 
#17 
MOG CTTGGAGGAAGGGACATGCA FAM/TAMRA 
Taqman-Mog 
Exon1 
mMog-Exon 1-AS #18 MOG CTC CAC AAA CAG GCC ATC TTT AT FAM/TAMRA 
Taqman-Mog 
Exon1 
mMog-Exon 1-Probe 
#19 
MOG AGGACCTCAGCTTGGCCTGACCCT FAM/TAMRA 
Taqman-Mog 
Exon1 
mMog-Exon 2-sense 
#14 
MOG CCCATCCGGGCTTTAGTTG FAM/TAMRA 
Taqman-Mog 
Exon2 
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mMog-Exon 2-sense 
#15 
MOG GCC CGT GGC ATT TTT CC FAM/TAMRA 
Taqman-Mog 
Exon2 
mMog-Exon 2-sense 
#13 
MOG CAGAGCTGCCGTGCCGCATC FAM/TAMRA 
Taqman-Mog 
Exon2 
2.2 Methods 
2.2.1 Animal Routine 
Alum immunization 
Mice were injected with 100 μg of rMOG i.p. in 200 μl per mouse. Protein is in 10% alum 
KAl(SO4)2 (Sigma) with 5 N NaOH (Merck). The precipitated protein solution and the alum 1:1 
were calibrated to a pH of 6.5-7.5 with NaOH (Merck). Then, the precipitated protein was 
incubated on ice for 30 min, washed 2 times with PBS and resuspended in PBS for i.p. 
injection. 
EAE induction  
EAE was induced by injecting the mice subcutaneously into the tail base with 200 μl of 
emulsion containing 200 μg MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) and 500 μg M. 
tuberculosis H37 Ra (Difco) in incomplete Freund Adjuvant oil (Difco). In addition, the mice 
received 400 ng pertussis toxin (List Biological Laboratories) intraperitoneally (i.p.) on days 0 
and 2 after immunization. Clinical signs of EAE were assessed daily according to the following 
criteria: score 0 – no disease; score 0.5 – reduced tail tonus; score 1 – limp tail; score 1.5 – 
limp tail and ataxia; score 2 – limp tail, ataxia and hind limb weakness; score 2.5 – at least 
one hind limb paralyzed/weakness; score 3 – both hind limbs paralyzed/weakness; score 3.5 
– complete paralysis of hind limbs; score 4 – paralysis until hip; score 5 – moribund or dead. 
Genotyping  
Transgenic mice were genotyped either by tail biopsy digested ON in tail digestion buffer 
followed by phenol-chloroform extraction of DNA (Roth, Karlsruhe) and PCR with transgene-
specific primers; by FACS analysis of PBMCs for expression of fluorophores or presence of 
certain surface markers; or by whole mount illumination to test for ubiquitous fluorophore 
expression in the skin in a custom-built illumination chamber. 
Intrathecal injection  
Dextran-FITC, Dextran AlexaFluor 488, 657 or mMOG FITC were intrathecally injected 
(Cisterna magna) into anesthetized mice. 8h later organs were taken for further analysis. 
Leukocyte isolation from peripheral blood  
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3 to 6 drops of blood were collected from anesthetized mice by retro-orbital bleeding into 
100 µl of 200 U/ml heparin (Sigma-Aldrich) in PBS. Erythrocytes were lysed by incubation in 
1 ml ACK buffer (5 min, RT) and leukocytes were spun down (500 rcf, 5 min, 4 °C). After 
repeating the ACK incubation and centrifugation, leukocytes were finally resuspended in 150 
µl FACS buffer. 
Mononuclear leukocyte isolation from organs  
Mice were anesthetized and perfused transcardially through the left ventricle with 20 ml cold 
PBS. Lymphoid organs (spleen, inguinal, axillary, mesenteric, CLNs, Peyer‘s Patches and 
intestine), brain and spinal cord were dissected.  
For lymphoid organs, single cell suspensions were prepared in RPMI by using 40 µm cell 
strainers (BD). Cells were centrifuged 10 min at 500 rcf 4 °C and cell pellet was resuspended 
in complemented RPMI for further analysis. For spleen preparation, erythrocyte lysis was 
performed by resuspending and incubating the cells in 0.83 % NH4Cl for 3 min at RT. Cells 
were washed with RPMI, centrifuged and resuspended in complemented RPMI.   
CNS was cut in pieces and digested with 1.25 mg/ml DnaseI and 3.75 mg/ml Collagenase D 
(Roche) for 30 min at 37 °C and single cell suspension was prepared in RPMI by using 100 µm 
cell strainers (BD). After centrifugation for 10 min at 500 rcf 4 °C, cell pellet was resuspended 
in 5 ml RPMI plus 2.16 ml Stock Isotonic Percoll (SIP) and was overlaid on 5 ml Percoll d=1.080. 
The gradient was centrifuged at 1200 rcf 30 min, RT and the interface, containing the 
mononuclear cells, was collected, washed with complemented RPMI and resuspended in 
complemented RPMI for further analysis. 
For intestine, duodenum, jejunum, and ileum were cut into small pieces and put in ice-cold 
CMF/Hepes. Intestinal pieces were washed by swirling a 10 cm cell culture dish onto 100 µm 
Nylonmesh. Intestinal pieces were transferred back to dish and 13 ml of ice-cold CMF/Hepes 
was added. Washing steps were repeated 3 times. After washing, intestinal pieces were 
transferred to Erlenmeyer flask and 25 ml of CMF/Hepes/EDTA were added. Tissue pieces 
were stirred for 15 min at RT on a magnetic stirrer (10 rcf). After incubation, content of flask 
was poured on Nylonmesh, new medium was added and washings were repeated for 3 times. 
Residual EDTA was removed by rinsing flask with RPMI-10, followed by washing pieces for 5 
min in RPMI-10, stirring for 5 min at RT. Then, intestinal pieces were incubated with 12 ml 
RPMI-10 with 100U/ml Collagenase D (Sigma) and stirred for 1h at 37 °C (30 rcf). Digested 
tissue was forced through a 100 µm Nylonmesh and washed twice with CMF/Hepes/EDTA. 
Pellet was resuspended in 5 ml 40% Percoll and put on 2.5 ml 80% Percoll in a 15 ml Falcon 
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tube. Cells were centrifuged for 20 min at 1200 rcf at RT. Cells were collected from interface 
and washed with RPMI, centrifuged and resuspended in complemented RPMI.   
Adoptive transfer EAE 
For induction of adoptive transfer (passive) EAE, iGB cells from in vitro cultures were 
centrifuged at 150 rcf for 10 min RT, washed once with iGB cell medium, and filtered through 
a 100 µm cell strainer. Cells were centrifuged and washed 2 times with PBS and filtered 
through a 40 µm cell strainer. 2D2 recipient mice were anesthetized and 200 µl of cells (15-
25 x 106) were injected intraperitoneally. Clinical symptoms were evaluated by classical EAE 
scores: score 0 – no disease; score 0.5 – reduced tail tonus; score 1: limp tail; score 1.5 – limp 
tail and ataxia; score 2 – limp tail and hind limb weakness; score 2.5 – at least one hind limb 
paralyzed/weakness; score 3 – both hind limbs paralyzed/weakness; score 3.5 –complete 
paralysis of hind limbs; score 4 – paralysis until hip; score 5 – moribund or dead. 
2.2.2 Cell culture routine 
Cell lysate preparation (native) 
Lysates were prepared by resuspending cells in 500 µl cell lysis buffer, followed by incubation 
for 30 min at 4°C. Lysates were spun down by centrifugation at 20,000 rcf for 1 hour (h), 
before supernatant was recovered and analyzed. 
Cultivation of cell lines 
Cell lines or primary cells were cultured in fully complemented RPMI or DMEM medium in 
standard cell culture-treated plastic dishes (BD; Nunc, Denmark; Corning) in a humidified 
incubator (Heraeus) at 37°C and 5% or 10% CO2, respectively. Cells growing in suspension 
were harvested by resuspending the culture; semi-adherent cells were flushed off the culture 
dish surface; and adherent cells were first briefly rinsed with PBS and then detached with 
Trypsin-EDTA (Sigma) for 3 to 5 min at 37°C. Cell numbers were regularly determined using a 
Neubauer hemocytometer (Neubauer). Cultures were kept subconfluent by regular dilution 
with fresh medium at ratios of 1:2, 1:10 or 1:20. Cells were pelleted by centrifugation at 150 
rcf for 10 min at 4°C and resuspended in complemented RPMI or DMEM for culturing or 
further downstream analyses. 
Cultivation of BMDCs 
BMDCs were prepared from femur of both legs. Femurs were rinsed in 70% EtOH to ensure 
sterility and epiphysis were removed with a scissor. Bone marrow was flushed out with cold 
incomplete RPMI and collected in a centrifuge tube. Cells were washed with 50 ml 
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incomplete medium and erythrocytes were removed using 0.84% ammonium chloride 
solution. After centrifugation cells were resuspended in complete RPMI and plated with 
density of 2.5 x 106 cells in bacteriological Petri dishes with 9 ml complete RPMI and 1ml 
medium collected from a GM-CSF producing hybridoma. On day 3 and 6 medium was 
exchanged with 8 ml complete RPMI and 2 ml medium collected from GM-CSF producing 
hybridoma cells. On day 8 cells were stimulated with 1 µg/ml LPS ON and fresh exosome free 
medium was applied. 
Cultivation of iGB cells 
IGB cell culture conditions were based on Kitamura’s instructions [116]. 40LB feeder cells 
were split the day before culture and fresh DMEM complete medium was added. Feeder cells 
were cultured in different densities and medium volume according to plate size (Table 11). 
On day 0, feeder cells were either irradiated (120 Gy γ-ray) or treated with Mitomycin C for 
1h (25 µg/ml) to stop further growth. Naïve B cells were either isolated from spleens of mice 
with a B cell isolation kit (Stemcell, 19854) or whole splenocytes were cultured on 40LB cells. 
B cells were cultured first for 4 days in the presence of 1 ng/ml IL-4 (BioLegend, 574304) in 
iGB medium and afterwards for 4 days in presence of 10 ng/ml IL-21 (BioLegend, 574506) 
with fresh (irradiated or Mitomycin-treated) 40LB cells. B cells were detached with warm 
PBS/BSA/EDTA (0.5 % BSA, 2 mM EDTA) for 5 min at RT. After day 4 and 8, B cells were 
counted and analyzed by FACS. For adoptive transfer, splenocytes were cultured for 4 days 
and then iGB cells were purified by washing (see 2.2.1). 
Table 11: Culture conditions of iGB cells for different plate types 
Freezing and thawing of stocks 
For preparation of long-term stocks, full dishes were harvested and resuspended in 500 µl 
10% DMSO in FCS. Stocks were frozen in a Cryo Freezing Container (Thermo Fisher Scientific, 
Dish size Surface 40LB cells B cells plated on day 1 
iGB cells plated 
on day 4 
iGB medium 
10 cm 55 cm2 1.2 x 106 
800 000 or 2.0 x 106 
(Adoptive transfer) 
50 000 
20 ml (day 0)   
10 ml (day 4) 
6 well 9 cm2 196 000 180 000 9900 9 ml 
12 well 4 cm2 87 000 80 000 4400 4 ml 
24 well 2 cm2 43 500 40 000 2200 2 ml 
48 well 1 cm2 21 800 20 000 1100 1 ml 
96 well 0.32 cm2 7000 4000 220 200 µl 
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Schwerte) at -80°C. For thawing, stocks were transferred to 37°C and washed once with 10 
ml fresh medium to remove DMSO, before resuspension in 10 ml warm medium. 
Proliferation assay   
2 x 105 B cells or iGB cells and T cells (1:5 ratio) per well were seeded in 96-well round-bottom 
plates in a total volume of 200 µl growth medium and stimulated with rMOG (20 µg/ml, 1:10 
dilution factor) or MOG Peptide 35-55 (20 µg/ml). After a culture period of 48 hours 2 µM of 
EdU (Thermo Fisher, A10044) was added per well. Samples were harvested 16 hours later 
and EdU incorporation was measured by FACS. 
2.2.3 Electron microscopy for exosomes 
For electron microscopy (EM) a drop of approximately 10 μg of exosomes in PBS was placed 
on a Parafilm. Then, with forceps, gently a formvar carbon coated nickel grid was positioned 
on top of each drop for 30-60 min. Three drops were placed, each 30 μl PBS on the Parafilm 
and grid was washed by sequentially positioning the grid on top of the droplets of PBS, and 
using an absorbing paper in between. Sample was fixed by deposit a drop of 2% 
paraformaldehyde on the Parafilm and grid was placed on top of the drop for 10 min. 
Washing step was repeated. Sample was fixed by adding a drop of 2.5% glutaraldehyde to 
the Parafilm and grid was incubated on top of the drop for 10 min. Sample was contrasted 
by adding a drop of 2% uranyl acetate to the Parafilm and grid on top of the drop for 15 min. 
Afterwards, sample was embedded by adding a drop of 0.13% methyl cellulose and 0.4% 
uranyl acetate to the Parafilm and grid on top of the drop for 10 min. Excess liquid was 
removed by gently using an absorbing paper, before positioning the grid on a paper with the 
coated side up and was air dried for 5 min. 
2.2.4 DNA techniques 
Agarose gel electrophoresis  
DNA fragments were separated in agarose gels (1.5% agarose in TAE buffer, 1 µg/ml 
ethidiumbromide) using approx. 1 V/cm2. DNA bands in analytical gels were visualized in the 
Geldoc XR system (Bio-Rad, München). For excision of DNA bands from preparative gels, long 
wavelength UV light (312 nm) on an IL 200 M transilluminator (Bachofer, Reutlingen) was 
used. 
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DNA amplification by PCR 
DNA was amplified by polymerase chain reaction using DreamTaq (Invitrogen, Karlsruhe), 
according to the instructions of the manufacturers, run on a PTC-200 DNAEngine (MJ 
Research, Bio-Rad, München) cycler. 
2.2.5 Enzyme linked immunosorbent assay (ELISA) 
ELISA plates (Nunc) were coated with rMOG (10 μg/ml in PBS), overnight at 4°C. Plates were 
washed and blocked for 1-2h. Afterwards plates were washed and incubated with 100 μl per 
well of samples at RT for 2 hours or ON at 4°C. Plates were then washed, and 100 μl per well 
of the respective biotinylated secondary antibodies (1:1000) in blocking buffer was added 
and incubated for 1 h. After extensive washing, streptavidin-HRP (1:2000) was added and 
incubated at RT for 30 min. After washing, 100 μl of TMB Substrate was added per well. After 
TMB stop solution was added, absorbance was measured at 450 nm in an ELISA reader 
(Victor2™ 1420 Mutilabel counter; Perkin Elmer life sciences). 
2.2.6 Exosome analysis 
Exosome producing cells were cultured in exosome-free media ON and supernatant was 
collected. Supernatant was first centrifuged for 30 min at 4000 rcf to deplete cell debris and 
then another 45 min at 10000 rcf to remove large membrane-derived vesicles. Finally, 
supernatant was centrifuged for 75 min at 100000 rcf to pellet small microvesicles. 
Afterwards, exosomes were characterized by either electron microscopy (2.2.3), western blot 
(2.2.11), nanosight or flow cytometry (FACS, 2.2.7). 
Nanosight based analysis 
With the Nanosight (Malvern Panalytical), exosomes can be analyzed by the nanoparticle 
tracking analysis. This is a method for visualizing and analyzing particles in liquids that relates 
the rate of Brownian motion to particle size. The rate of movement is related to the viscosity 
and temperature of the liquid. With this method, the determination of a size distribution 
profile of small particles with a diameter of approximately 10-1000 nm in liquid suspension 
is shown. Exosomes are resuspended in PBS and directly analyzed.  
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2.2.7 Fluorescence-activated cell sorting (FACS) 
For cells 
Cells to be analyzed were transferred into 96-well V-bottom plates and centrifuged at 250 rcf 
for 10 min at 4°C. Cells were washed in 150 µl FACS buffer twice, resuspended in 50 µl FACS 
buffer containing directly labeled surface marker-binding antibodies at appropriate dilutions 
and Fc block (1:2000, BD Bioscience), and incubated for 20 min at 4°C. After washing and 
resuspension in 150 µl FACS buffer, samples were acquired on a FACS VERSE (BD, Heidelberg), 
and analyzed using FlowJo 7.6 software (TreeStar, Ashland, OR, USA). 
For exosomes 
To analyze exosomes 30 μg purified exosomes as measured by Bradford assay were 
incubated with 10 μl latex beads (surfactant-free aldehydesulfate, 4 % solids; Interficial 
Dynamics 12-4000) for 15 min at RT, in a 1.5-ml tube. PBS was added to a final volume of 1 
ml and mixture was incubated on a tube rotator wheel ON at 4°C. To block free binding sites 
on beads, 110μl of 1 M glycine (i.e., 100 mM final) were added, mixed gently and incubated 
on the bench at RT for 30 min. Exosomes were centrifuged for 5 min at 2000 rcf, RT. 
Supernatant was removed and discarded. Bead pellet was resuspended in 1 ml FACS-Buffer 
and centrifuged for 5 min at 4000 rpm, RT. Supernatant was discarded and bead pellet was 
resuspended and centrifuged in 1 ml FACS-Buffer. Then, pellet was resuspended in 200 μl 
FACS Buffer and transfered to V-bottom plate with 10 μl coated beads per well. 50 μl anti-
exosomal protein antibody diluted in FACS Buffer (1:200) was added and incubated 30 min 
at 4◦C in the dark. After washing and resuspension in 150 µl FACS buffer, samples were 
acquired on a FACS VERSE, and analyzed using FlowJo 7.6 software. 
2.2.8 Immunohistochemistry 
Organs from PFA perfused mice were fixed in 4% PFA in PBS for 1 hour, and then immersed 
in 30% sucrose, overnight. Tissues were embedded in tissue-tek O.C.T. compound (Sakura), 
and 7 µm sections were cut on a CM3050 S Cryocutter (Leica). Tissue sections were thawed, 
fixed in cold acetone for 10 min, and blocked with 5% BSA in PBS for 2h at RT. Incubation 
with primary antibody was done in 5% BSA in PBS ON at 4°C. Incubation with secondary 
antibody was done in 5% BSA in PBS for 2 h at RT. Cell nuclei were stained with DAPI 
(Invitrogen, Karlsruhe) in PBS for 5 min at RT, before sections were rinsed with H2O and 
embedded in anti-fading mounting medium (Sigma-Aldrich, Taufkirchen). Images were 
acquired on an inverted SP2 confocal microscope (Leica, Wetzlar) or an inverted AxioVert 
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200M microscope (Carl Zeiss, München). Individual images were assembled for overviews of 
whole organs using ImageJ (Wayne Rasband). 
2.2.9 Production of MOG tetramer 
Mouse MOG1-125 was transiently expressed in human embryonic kidney cells (HEK) 
transformed with EBNA-1 gene cell line. Purified MOG1-125 protein from HEK cells was 
biotinylated with BirA ligase in order to multimerize them to form tetramers. Tetramerization 
was achieved based on the ability of streptavidin (SA) to spontaneously assemble stable 
tetramer-structures composed of four biotinylated MOG1-125 protein monomers (MOGtet). 
Since the SA used was directly conjugated to fluorophores like AF488 or PE, MOGtet could 
be used as detection tool for MOG specific B cells via flow cytometry. 
2.2.10 RNA techniques  
RNA extraction  
Total RNA was isolated from purified cells by TRI Reagent (Sigma-Aldrich, Taufkirchen) 
following the instructions provided by the manufacturer. 
Reverse transcription 
cDNA was generated from RNA using SuperScript II Reverse Transcriptase (Invitrogen, 
Karlsruhe) or the Verso cDNA Kit (Thermo Fisher Scientific, Schwerte), according to the 
manufacturer´s instructions. 
Quantitative PCR 
Real-time qPCR was performed using the ABsolute QPCR Mixes (Thermo Fisher Scientific, 
Schwerte) according to the instructions of the manufacturer, and samples were run on a 
7900HT Fast Real-Time PCR System and analyzed by SDS 2.3 software (both Applied 
Biosystems, Darmstadt). 
2.2.11 Western Blot 
BCA assay 
Protein concentration was estimated using the BCA protein assay following the 
manufacturer´s instructions (Thermo Scientific Pierce, Rockford, IL, USA). 
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SDS-PAGE  
Separation of proteins was achieved by denaturing, discontinuous, one-dimensional SDS 
polyacrylamide gel electrophoresis (Lämmli, 1970), using pre-cast Novex 4-12% tris-glycine 
gels (Invitrogen, Karlsruhe). 2x Lämmli buffer was added to 10 µl cell lysate, boiled for 5 min 
at 100°C, and loaded to each lane. Electrophoresis was performed in Lämmli running buffer 
at 100 V for stacking, and at 130 V for resolving of proteins in a Mighty Small gel chamber 
(Hoefer, San Francisco, CA, USA). To verify appropriate sample loading, gels were stained 
with Coomassie Brilliant Blue G-250 (Bio-Rad, München). 
Western transfer   
Proteins were electrophoretically transferred from polyacrylamide gels to Immobilion-FL 
PVDF membranes (Millipore, Schwalbach) using the semi-dry blot technique. Configuration 
of the Western blot was: 6 layers Whatman paper wetted in anode buffer I, 3 layers Whatman 
paper pre-wetted in anode buffer II, PVDF membrane (pre-equilibrated in methanol), 
polyacrylamide gel, 6 layers Whatman paper wetted in cathode buffer. The transfer was 
carried out at a current of 0.8 mA/cm2 for one hour at RT. 
Immunodetection of proteins   
All incubations were done on a rocking table. After transfer of proteins, the membrane was 
blocked by incubation in PBS with 5% milk powder ON at 4°C. The primary antibody was 
diluted in PBS 0.1% Tween-20 1% milk powder. Primary antibody incubation was done for 1 
hour at RT. After four washes with PBS 0.2% Tween-20 for 5 min, the membrane was 
incubated with HRP-coupled secondary antibody in PBS 0.1% Tween-20 1% milk powder for 
1 hour at RT in the dark. The membrane was washed four times for 5 min; final washing was 
done in PBS without Tween-20. Bands were detected using ECL Western Blotting Substrate 
(Thermo Scientific Pierce, Rockford, IL, USA) on Amersham Hyperfilm ECL (GE Healthcare, 
München). 
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3 RESULTS 
3.1 Antigen transport and priming of autoreactive lymphocytes in 
spontaneous EAE 
Presentation of auto-antigen to B and T cells is a crucial event in the development of EAE. 
However, when and where autoreactive lymphocytes encounter antigen is not well 
understood, especially in spontaneous EAE models. One hypothesis is that APCs and/or 
soluble auto-antigens may migrate from the CNS to regional lymph nodes to initiate an 
autoimmune response [72]. In this chapter, the possible drainage pathways of myelin 
antigens to CLN in soluble form or exosomes were investigated, as well as B cell activation in 
the gut as a potential activation site.  
3.1.1 Detection of CNS draining pathways with fluorescent tracers 
In order to visualize the drainage pathway from the CNS to regional lymph nodes and 
determine, which cell types may be involved in the transport, different fluorescent tracers 
were employed. SJL/J WT mice were intrathecally injected with either 20 µg of dextran FITC, 
Alexa Fluor 488, Alexa Fluor 647 or PBS. Different flurophores were tested to optimize the 
signal. After 24h, mice were killed and different organs were analyzed for the presence of 
those fluorescent tracers by FACS (Figure 2 A-E). Higher frequencies of dextran+ cells were 
detected in the CNS (A-B), deep (d) and superficial (s) CLN (B) compared to low frequencies 
in spleen, axillary (aLN) and inguinal lymph nodes (iLN). In the CNS, B220+ B cells, CD11c+ 
dendritic cells and CD11b+ macrophages equally carried dextran-FITC (data not shown), 
whereas in d CLNs and s CLNs dextran was mostly carried by CD11b+ cells (C-E). As expected, 
dextran was not detectable on non-APC populations like CD4+ T cells. 
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Figure 2: Cervical lymph nodes are drainage sites for intrathecally injected dextran. 
SJL/ J WT mice were intrathecally injected with 20 µg of dextran FITC (green bars), dextran Alexa 488 (dark green), 
dextran Alexa 647 (purple) or PBS (black bars), organs were taken after 24 hours and analyzed by flow cytometry. 
A) Plots show gating strategy and frequency of dextran-FITC+ cells in CNS. B) Summary of dextran+ cells in CNS, 
deep and superficial cervical, axillary, inguinal lymph nodes and spleen. C) Dextran-FITC+ cells in different cell 
types in d CLNs. Left three plots show gating strategy for B cells (CD45+CD19+), T cells (CD45+CD4+), dendritic cells 
(CD45+CD11c+) and macrophages (CD45+CD11b+). Plots on the right show frequency of Dextran-FITC+ cells among 
the respective population. D-E) Summary of results in deep (D) and superficial (E) CLNs. Data of two independent 
experiments with n=2 mice per group are shown. Graphs show mean ± SEM. 
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Since dextran FITC showed slightly increased frequencies during intrathecal injection and is 
smaller in size than Alexa Fluor 488, it was further used for the labeling of mammalian MOG. 
To investigate if myelin antigens translocate from CSF to CLNs, 20 µg mammalian MOG-FITC 
or PBS was injected intrathecally in combination with 20 µg dextran Alexa 647 as positive 
control (Figure 3). Intrathecal injection of MOG-FITC and dextran Alexa 647 shows MOG-FITC+ 
cells in the CNS (Figure 3 A), but positive cells were neither found in d CLNs nor in s CLNs, 
whereas dextran Alexa 647 was found in both indicating that injection process was successful 
(Figure 3 B). As in the previous experiment, dextran 647 was mostly carried by CD11b+ cells, 
however, there was no evidence that MOG-FITC was carried by those cells (data not shown).  
 
 
Figure 3: After intrathecal delivery MOG-FITC does not translocate to CLNs.  
SJL/ J WT mice were intrathecally injected with 20 µg of MOG-FITC (red bars), dextran Alexa 647 (blue) or PBS 
(black bars), organs were harvested after 24 hours and analyzed by flow cytometry. A) Plots show gating strategy 
and frequency of MOG-FITC+ cells and dextran Alexa 647+ cells in CNS. B) Summary of frequencies of MOG-FITC+ 
and dextran+ cells in different organs. Mean ± SEM of two independent experiments with n=2 mice per group are 
shown. 
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To exclude potential degradation of intrathecally injected conjugated fluorophores, PLP-GFP 
reporter mice were used to track transport of PLP during active EAE. PLP-GFP is a fusion 
protein and has higher stability than conjugated fluorophores. Fusion proteins might be more 
resistant to internal decomposition by macrophages and therefore PLP-GFP may be more 
suitable to show antigen transport in EAE. Mice were immunized with MOG35-55 peptide in 
complete Freund’s Adjuvant and injected with Pertussis toxin on day 0 and 2 to induce active 
EAE. Mice were sacrificed before and at onset of disease (day 8 and 10 after immunization) 
and different organs were analyzed for the presence of PLP-GFP positive cells by FACS (Figure 
4). During onset very few GFP+ leukocytes were visible in the spleen of PLP-GFP reporter mice 
compared to WT BL6 mice but not in other organs. During the peak of disease there were 
almost no GFP+ cells detectable in any organ.  
 
 
Figure 4: PLP-GFP is not visible in draining lymph nodes of CNS during EAE. 
Mice were analyzed on day 8 and 10 after immunization by FACS. Graph shows frequency of GFP+ cells among 
CD45+ cells in different organs. Mean ±SEM of two independent experiments with n=3 for onset (Score 1, 1, 2) 
and n=3 for peak (Score 2, 2, 3) are shown.  
 
 
3.1.2 Detection of CNS autoantigens in CLNs with immunohistochemistry 
To address the question if auto-antigen is transported from the CNS to regional lymph nodes 
and whether it is associated with a certain cell type, visualization of myelin antigens within 
the CLNs via immunohistochemistry was attempted.  
Immunohistochemical staining with antibodies against the myelin proteins PLP, MBP and 
MOG was established (Figure 5 A-D). MBP+ (A), PLP+ (B) and MOG+ (C) cells were localized in 
medullary cords or subcapsular sinus (structures that contain mostly macrophages) but were 
not found within T cell (CD4+) or B cell (B220+) zones of CLNs. MBP+, PLP+ and MOG+ cells were 
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visible in sick RR mice (score 2.5) as well as in non-transgenic littermates (NTLs). No positive 
signal was detected in isotype control - treated samples. 
Since we observed positive staining for myelin antigens not only in the sick RR mice but also 
in healthy NTLs (Figure 5 A-C), additional staining with anti-MOG F(ab)2 antibody was 
performed to exclude unspecific staining caused by antibody capture through Fc receptors 
(D). Using anti-MOG F(ab)2 antibody (Z2-F(ab)2) no staining could be detected in the CLNs of 
sick RR mice and NTLs, although the positive control in spinal cord tissue showed MOG 
staining indicating that the anti-MOG F(ab)2 antibody faithfully detected MOG. 
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Figure 5: Staining for myelin proteins in cervical lymph nodes of sick RR mice and non-transgenic littermates. 
Microscopic images of CLN sections from sick RR mice (score 2-3) and NTLs, (A) Myelin basic protein (MBP) is 
shown in green, (B) proteolipid-protein (PLP) in green, (C) MOG in green (with 8.18c5 antibody), (D) MOG in green 
(with Z2 F(ab)2 antibody), anti-CD4 staining for T cells in red, anti-B220 staining for B cells in white and DAPI in 
blue. As a positive control spinal cord sections were stained with the same antibodies against MBP, PLP, and MOG. 
Representative data of 3-4 individual mice are shown. Magnification 20 x. Scale bar 100 µm. 
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Given that MOG-positive staining was predominantly found in the subcapsular sinus of CLNs 
co-staining with the macrophage markers CD11b or CD68 was performed on tissue from NTLs 
and MOG-/- mice to determine whether macrophages capture the anti-MOG antibody 
unspecifically. MOG and CD11b/CD68 signals co-localized within the same area in the lymph 
node in NTLs but also in MOG-/- mice suggesting an unspecific binding of the anti-MOG 
antibody (8.18c5) to Fc receptors on macrophages (Figure 6). This indicates that this could 
also be the case for PLP and MBP signals. However, it cannot be concluded that the myelin 
proteins are not present in the CLN, only that they cannot be reliably detected. They could 
be degraded so that antibodies are no longer able to recognize them. 
 
 
Figure 6: Staining for MOG and CD11b or CD68 on CLN of non-transgenic littermates and MOG-/- mice 
Microscopic images of CLN sections of NTLs (n=3) (upper panel) and MOG-/- mice (n=2) (lower panel), MOG 
staining is shown in green, CD68 staining for macrophages in red, and DAPI in blue. Magnification 20 x. Scale bar 
100 µm.  
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3.1.3 Detection of MOG in exosomes from different cell types 
Since we could not observe draining of soluble MOG-FITC from the CNS to the CLNs (Fig.3), 
the possibility that myelin antigens are transported via exosomes was explored next. 
Exosomes from MS patients have been shown to express myelin protein, correlated with 
disease activity and were highest in relapsing-remitting MS [118]. Therefore, the role of 
exosomes as a potential delivery system of auto-antigens was investigated. Isolation of 
exosomes from EL4 cells, EL4-MOG cells and bone marrow-derived dendritic cells (BMDCs) 
from WT or H2M mice was established. As exosomes can originate from different cell 
sources, EL4 cells derived from T cell lymphoma and corresponding EL4-MOG cells which 
express MOG on their surface, as well as BMDCs from WT and MOG expressing H2M mice 
were used to investigate the potential of exosomes to transport MOG.  
In order to establish isolation and characterization of exosomes, EL-4 cells were grown in 
exosome-free media. Exosomes were isolated from the culture supernatant via several 
centrifugation steps and characterized by electron microscopy, western blot, nanosight or 
FACS. In the literature, typical characteristics for exosomes are size and presence of markers 
for multivesicular body formation [87, 119]. Previous studies documented exosomes to be 
smaller than 150 nm in size and to express exosome intracellular markers like Alix, a regulator 
of the endo-lysosomal system, and Tsg101 which has been associated with the biogenesis of 
multivesicular bodies [120]. Also, extracellular markers like CD63 and CD9, depending on 
cellular origin of the exosome, have been described as markers for exosomes [121].  
Analysis of the microvesicles isolated from EL4 cells and BMDCs by electron microscopy 
showed round membrane-structures between 50-120 nm (Figure 7), indicating that they 
fulfill the size criterion described for exosomes.  
 
Figure 7: Isolation of exosomes from EL-4 cells and BMDCs. 
Electron microscopy images of microvesicles isolated from EL-4 cells (left) and BMDCs (right) reveal rounded 
membranaceous structures measuring on average less than 150 nm. Scale bars, 100 nm; original magnification 
100,000 x. Representative data from 3 individual experiments. 
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Characterization of EL4 cell-derived microvesicles by nanosight, a technique that utilizes 
Nanoparticle Tracking Analysis to characterize nanoparticles from 10 - 2000 nm in solution, 
showed a mean particle size of 130 nm (Figure 8 A) similar to the previously documented size 
of exosomes. Flow cytometric analysis of EL4-MOG derived exosomes showed the presence 
of the cell surface markers CD9, CD63 and CD90.2 (Figure 8 B). Moreover, exosomes derived 
from EL-4 MOG cells showed positive staining for MOG compared to exosomes derived from 
EL-4 cells. Exosomes isolated from BMDCs of C57BL/6 used as controls and H2M mice, which 
overexpress MOG on every cell type, showed similar characteristics. Consistent with their 
cellular origin exosomes from BMDCs also carried CD86, CD80 and MHC class I on their 
surface. Additionally, H2M exosomes expressed MOG on the surface in contrast to exosomes 
from C57BL/6 BMDCs (Figure 8 B). Markers of multivesicular body formation including Alix 
and Tsg101 and MOG were detected in protein lysates from EL-4 MOG cells and exosome 
lysates by Western blot (Figure 8 C). In contrast to cell lysates, the endoplasmatic reticulum 
marker calnexin was absent in the exosome fraction indicating purity of exosomes. 
Immunolabeling for Tsg101 was stronger in exosomes than in cell lysate suggesting 
microvesicles originate from vesicle budding. Moreover, MOG seemed to be enriched in 
exosomes. In addition, levels of MOG mRNA in EL-4 MOG and EL-4 exosomes were analyzed 
via qPCR, and showed an enrichment of MOG mRNA in exosomes derived from EL-4 MOG 
cells (Figure 8 D). As expected, no expression of MOG was detected in exosomes derived from 
EL4 cells. Thus, these exosomes containing MOG could be used for further studies 
investigating their potential to activate autoreactive T and B cells. 
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Figure 8: Characterization of EL4, EL4-MOG and BMDC-derived exosomes. 
A) Exosomes in solution are measured via Nanosight. Left upper plot shows particle size and concentration of 
exosomes in solution. Right upper plot shows a snapshot of a video of motion of exosomes in solution. Lower left 
plot shows selection of particle size for calculation. Lower right plot shows 3D distribution of particle size to 
relative density. Vesicles are analyzed by the rate of Brownian motion to particle size. Representative data from 
2 individual experiments. B) FACS analysis of exosomes isolated from EL4-MOG cells and H2M BMDCs. Red lines 
show beads coupled with exosomes, incubated with antibodies. Blue lines represent beads only incubated with 
antibody as negative control. C) Lysate of EL-4 MOG cells and corresponding exosomes were analysed by western 
blot, testing for the exosomal markers Alix and Tsg101, endoplasmatic reticulum marker Calnexin, and MOG, using 
specific antibodies. Graph is representative of 3 individual experiments. D) Relative expression of MOG mRNA in 
EL4-MOG derived exosomes (black bars) and in EL4 derived exosomes (red bars).  
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3.2 B cell activation studies in the intestine  
The stimuli leading to activation of autoreactive lymphocytes have been commonly 
attributed to environmental factors such as composition of the microbiota. In a previous 
study from our laboratory it was demonstrated that RR mice housed under completely germ-
free conditions are protected from spontaneous EAE due to impaired Th17 cell 
differentiation in the intestine and MOG-specific B cell recruitment [68, 122]. After re-
colonization, mice promptly developed disease again. Thus, a two-phase scenario was 
proposed that starts out in the GALT with expansion and activation of autoreactive T cells, 
which then recruit autoantibody-producing B cells and migrate to the CLNs and CNS. 
However, it is unclear whether autoreactive B cells are initially activated together with 
autoreactive T cells in the gut either by bystander activation or via molecular mimicry by 
microbial antigens and consequently migrate to the CLNs and/or the CNS to promote the 
development of EAE, or whether autoreactive B cells are exclusively primed in the CLNs. In 
order to perform B cell activation and migration studies, B cells with fluorescent reporters 
were adoptively transferred into recipient mice. To be able to track where MOG-specific B 
cells migrate over time during development of EAE, GFP reporter mice were utilized. To 
establish the experimental system, first, splenocytes were isolated from actin-GFP mice, in 
which all cells express GFP, and 25 x 106 total splenocytes were injected intraperitoneally into 
WT mice. 3, 5 and 7 days after transfer, different organs of the recipients were screened for 
the presence of GFP+ B cells. GFP+ B cells were found in low frequencies in Peyer’s Patches 
(PP), spleen (Spl), aLNs and mesenteric (mLNs), as well as in duodenum (Duo), ileum (Il) and 
colon (Co) (Figure 9 A, B). 
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Figure 9: Transfer of actin-GFP cells into WT mice results in low frequencies of GFP+ cells in intestinal segments. 
A) Plots show gating strategy and frequency of GFP+ B cells. B) Frequency of actin-GFP B cells in different organs 
at indicated time points after transfer of total splenocytes. 25 x 106 total splenocytes from actin-GFP mice were 
injected into WT mice. Mice were killed on day 3, 5 and 7 after injection and organs were analyzed by FACS. C) 
Frequency of actin-GFP B cells in different organs at indicated time points after transfer of purified B cells. 10 x 
106 purified B cells from actin-GFP mice were injected into WT mice (n=2 per time point). D) Purification of 
C 
B 
D 
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mononuclear cells from the intestinal segments via density gradient. Mean ± SEM of two independent 
experiments with n=2 mice per group are shown.  
Lowest frequencies of GFP+ B cells were found in duodenum, ileum and colon. In an attempt 
to increase frequencies of surviving B cells, purified actin-GFP B cells were injected into WT 
mice. However, while low frequencies of GFP+ B cells were visible in spleen, PP, aLNs and 
mLNs, B cells were not detectable in duodenum, ileum and colon (Figure 9 C). To improve 
recovery of B cells from the lamina propria, cell isolation was optimized with Percoll density 
gradient centrifugation. Using this method at least some GFP+ B cells could be detected in 
duodenum, ileum and colon (compare Figure 9 C and D); however, overall frequencies of B 
cells remained very low.  
In addition to low frequencies, analysis of transferred B cells was further complicated by the 
sensitivity of the GFP signal to fixation and intracellular staining procedures. For later 
cytokine profile studies by FACS, cells have to be fixed and permeabilized in order to perform 
intracellular cytokine staining. B cells can produce several different cytokines and can be 
subdivided into discrete cytokine-producing “regulatory” and “effector” B cell subsets. 
Regulatory B cells (Breg) are distinguished by their ability to secrete IL-10, IL-35, or TGFβ-1, 
while effector B cell populations produce cytokines such as IL-2, IL-4, GM-CSF, IL-6 or IFNγ, 
IL-12 and TNFα [67]. Unfortunately, fixation and permeabilization of actin-GFP cells led to 
loss of GFP signal (Figure 10 A). In order to best preserve the GFP signal during all stainings, 
different fixation and permeabilization conditions were tested. After fixation for 5-30 min 
and intracellular staining of cells, GFP staining was completely lost. Washing without 
permeabilization buffer did not rescue the GFP+ signal. Previous reports suggested that pre-
fixation with PFA may prevent loss of fluorescent signals. Therefore, stainings with different 
pre-fixation conditions after surface staining were tested. Pre-fixation of cells reduced the 
loss of GFP signal, however, the signal was still not comparable to signal obtained with 
unfixed and unpermeabilized cells. Furthermore, a GFP Booster (Chromotek) which allows 
stabilization of fusion proteins was tested. However, the GFP Booster also only partially 
preserved the GFP signal (Figure 10 B). 
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Figure 10: Loss of GFP signal during intracellular staining and washing. 
A) Splenocytes isolated from actin-GFP mice were washed in FACS buffer without fixation/permeabilization 
(upper panel) or fixed and washed with permeabilization buffer for intracellular staining (middle panel). Lower 
panel shows WT cells as control. B) Intracellular staining of actin-GFP splenocytes with GFP booster. Cells are 
gated on CD45+, CD19+ and GFP+ cells. Data of 2 individual experiments are shown.  
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3.3 In-vitro induced GC B cells are a new tool for B cells studies in EAE 
B cell activation is a crucial step in the initiation of MS and it has been shown that B cells are 
also essential for the development of spontaneous EAE [34]. However, it is not clear where 
autoantigen-specific B cells are originally activated and recruited. Upon transfer MOG-
specific B cells migrate to germinal centers in CLNs in RR mice indicating that CLNs may be an 
important site for B cell activation. However, due to the extremely low frequency of 
endogenous MOG-specific B cells in RR mice (≤ 1%) it is very challenging to study their origin, 
development, migration pattern and pathogenic properties (such as repertoire, phenotype, 
cytokine profile etc.). In addition, the frequency of endogenous MOG-specific B cells is too 
low to be able to manipulate them ex vivo and use them for transfer studies. To overcome 
these limitations, a cell culture system originally developed by Kitamura and colleagues [116] 
was established which allows us to expand primary B cells over several days and differentiate 
them into GC B cells and plasmablasts (Figure 11). The activated, in vitro induced GC B cells 
(iGB) and plasmablasts can be used for B cell studies in EAE. In this chapter, establishment of 
the culture system and transfer of iGB cells were investigated.  
 
Figure 11: Schematic representation of the iGB culture system. 
Primary B cells are cultured on a layer of irradiated or Mitomycin C treated 40LB cells in the presence of IL-4 for 
4 days (Primary culture). Then, proliferated iGB cells are transferred onto fresh 40LB cells for 4 days in the 
presence of IL-21 (Secondary culture). Afterwards, B cells are analyzed for expression of GC and plasmacell 
markers, as well as isotype switch via FACS. 
 
3.3.1 The iGB cell culture system 
In response to T cell-dependent antigens, B cells proliferate extensively to form GC, and then 
differentiate into memory B cells or long-lived plasma cells. In the T cell dependent response, 
antigen specific B cells present the antigen to primed cognate T helper cells in the lymphoid 
follicles and clonally proliferate upon receiving signals via CD40-ligand (CD40L) and IL-4 from 
RESULTS 48 
the T helper cells. The CD40 - CD40L interaction is required for T helper cell - mediated B cell 
activation and thus for GC formation, and for generation of memory B cells [123]. In addition, 
IL-21 signalling is required for high proliferation rates, IgG1 production, efficient GC 
formation, affinity maturation and long lived plasma cell formation, but not for memory B 
cell development in mice [124]. IL-21 induces class switch recombination (CSR) to IgG and 
Blimp1 expression. Therefore, the culture system is based on signals mediated by CD40-
CD40L interaction, BAFF and the cytokines IL-4 and IL-21 to drive B cell proliferation, 
differentiation and survival. Kitamura and colleagues created a BALB/c 3T3 fibroblast cell line, 
which constitutively expresses CD40L and BAFF (40LB feeder cells). Together with additional 
cytokines (IL-4 and IL-21) these cells act as a replacement for T helper cells and provide the 
required stimuli for B cells to expand and differentiate in vitro. 40LB feeder cells have to be 
irradiated in order to not overgrow B cells and influence culture conditions. 
To set up the culture system, B cells were first isolated from spleens of BL6 or SJL/J mice and 
cultured in the primary culture for 4 days on irradiated or mitomycin treated 40LB feeder 
cells in the presence of IL-4. For the secondary culture, B cells from the primary culture were 
collected and were again cultured for 4 days in presence of IL-21 with fresh irradiated 40LB 
cells (800.000 B cells are seeded per 10 cm dish). After the primary (day 4) and secondary 
culture (day 8), B cells were counted and analyzed by FACS. B cells cultured without cytokines 
are not able to perform isotype switch or differentiate into plasmablasts and are used as 
control group. In Figure 12 A an overview picture of the iGB culture on day 0 and 4 is shown. 
By day 4 B cells formed proliferation clusters on 40LB cells. Overall, the expansion factor of B 
cells differed between primary and secondary culture, but not between mouse strains (Figure 
12 B-C). In the presence of IL-4, B cells expanded 3-10 fold, whereas presence of IL-21 in the 
secondary culture induced up to a 500-fold expansion (Figure 12 D).  
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Figure 12: Expansion of B cells derived from different mouse strains in primary and secondary iGB culture. 
A) Brightfield microscopy of proliferating B cells cultured on 40LB cells. Microscopic images of iGB cell culture 
dishes on day 1 (left) and 4 (middle and right) Scale bar 50 µm. Magnification 20x. Arrows show proliferating 
clusters of B cells. Magnification 10x (right panel 20x) B) Graph shows expansion of B cells isolated from BL6 and 
SJL mice during primary culture in the presence of IL-4 (day 1-4). C) Graph shows expansion of B cells isolated 
from BL6 and SJL mice during secondary culture in the presence of IL-21 (day 4-8). D) Expansion factor of B cells 
derived from BL6, SJL, RR and R&D SJL mice cultured 4 days with IL-4 (red bars) followed by 4 days with IL-21 (blue 
bars), or without cytokines (black bars). Graphs show mean ± SEM from 3 independent experiments with n ≥ 3 
mice per group. 
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Next, phenotyping of B cells in the iGB culture was performed via flow cytometry. At the end 
of the primary culture, IL-4 had induced BCR class switching from IgM to IgG1 in about 10-
20% of B cells (Figure 13). After the secondary culture in the presence of IL-21, B cells had 
completed the isotype switch, i.e. they did not express IgM anymore and the majority (60-
80%) now expressed IgG1. Compared to Kitamura’s studies [116], a much lower frequency of 
IgE+ cells during the entire culture period was obtained. Development of IgA+ B cells, as well 
as IgG2a+ and IgG2b+ B cells was rare in all mouse strains (Figure 13 and data not shown). As 
expected, the frequency of CD138+ plasmablasts increased over time, especially during the 
secondary culture. However, overall plasmablast frequency was quite variable between 
experiments. All B cells except CD138+ cells exhibited a germinal center B cell phenotype 
characterized by expression of GL7+, Fas+, and PNA+ and downregulation of the naïve B cell 
marker CD38. No differences in B cell phenotype among different mouse strains were 
detected. 
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Figure 13: Flow cytometric analysis of indicated markers in iGB cells cultured with IL-4 and IL-21. 
Expression of FAS, GL7, PNA and CD38 were analyzed in 7AAD- and CD138- cells after primary (day 4) and 
secondary culture (day 8). IgM, IgA, IgE and IgG1 expression was analyzed in cells gated on CD138- and H2Kd- cells 
after primary (day 4) and secondary culture (day 8). Graphs show Mean ± SEM from 3 independent experiments 
with n ≥ 3 mice per group. 
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3.3.2 Adjustment of the iGB culture system for low B cell numbers 
To grow small numbers of B cells isolated from various organs, the effect of dish size on B cell 
expansion was tested (Figure 14). In the primary culture the expansion rate of iGB cells in 
different dish sizes was consistent. In contrast, the expansion factor of iGB cells in the 
secondary culture was higher in 10cm dish, 6 and 12 well plates compared to the smaller 
formats (24, 48 and 96 well plates). Characterization of phenotype via flow cytometry 
showed similar GC B cell marker expression as well as BCR class switching in all formats (data 
not shown).  
 
Figure 14: Expansion of iGB cells in different cell culture plates. 
B cells were plated on 40LB cells for 8 days. Mean ± SEM from 5 independent experiments with n = 2 is shown. 
 
To test the effect of purity on B cell expansion, B cells were either purified to ≥95% with a B 
cell isolation kit or whole splenocytes were cultured on 40LB cells (Figure 15). Under both 
conditions, B cells were expanding equally well and showed similar expression of GC B cell 
markers and isotype switch (Figure 15 B-D). Other cell types including T cells, macrophages 
and DCs largely died during the iGB culture after 4 days. Although there are still some 
macrophages and T cells detectable, they do not expand and seem to have no influence on 
B cell expansion and differentiation (Figure 15 A). Furthermore, culture of B cells derived 
from the CNS of a sick rMOG immunized SJL/J mouse without prior purification was 
successful. CNS-derived B cells also showed GC marker expression (Figure 15 E). Importantly, 
CNS-derived B cells produced higher titers of total anti-MOG IgG than B cells derived from 
spleen (Figure 15 F). These data suggest that purification of B cells before iGB culture is not 
required. Since only B cells receive survival and proliferation signals in the iGB culture system, 
the risk of losing rare B cells such as autoantigen-specific B cells from the CNS during 
purification processes can be reduced by plating all cells. 
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Figure 15: Comparison of total splenocytes, purified, and CNS-derived B cells in the iGB culture. 
A) Representative FACS analysis of the iGB culture on day 4 using either whole splenocytes or purified B cells as 
starting material. CD45+ cells in the culture were analyzed for presence of different cell types including B cells 
(CD19, B220), macrophages (CD11b), dendritic cells (CD11c) and T cells (CD4, CD3). B-D) Phenotypic comparison 
of primary (d4) and secondary (d8) iGB cultures using either total splenocytes (red bars) or purified B cells (blue 
bars) as starting material. Cells were analyzed for expression of GC markers (B), as well as isotype switch from 
IgM (C) to IgG1 (D). Mean ± SEM from 1 experiment with n = 3 is shown. E) Expansion of CNS-derived B cells from 
a sick rMOG immunized mouse on day 4 of culture. Cells are gated on 7AAD-, CD138- and CD19+ cells and analyzed 
for GC markers (FAS, GL7, PNA and CD38) and isotype switch (IgM, IgG1, IgE and IgD). F) Amount of total IgM, 
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total IgG1 and MOG-specific IgG antibodies in the supernatant of iGB cultures from CNS vs. spleen derived B cells 
from a MOG-immunized mouse was determined by ELISA. 
3.3.3 Tracking tools for iGB cells in vitro and in vivo 
To examine if B cells expressing fluorescent reporter proteins can be expanded in vitro for 
tracking B cell migration/fate upon transfer, GFP+ B cells from actin-GFP mice and RFP+ B cells 
from R&D mice were tested in the iGB culture (Figure 16 A). Unfortunately, RFP signal 
decreased drastically during culture and was not detectable any longer after 4 days of 
culture. Even though GFP signal was stable until day 4 it also decreased during secondary 
culture. Fluorescent signal decreases probably due to high proliferation rates of iGB cells, but 
may come back upon adoptive transfer. However, these fluorescent reporters may not be 
the perfect tool to detect all transferred B cells especially if they are expanding rapidly.  
Due to detection problems with fluorescent reporter proteins tracking of donor B cells via 
allotype was investigated. TH mice were backcrossed onto both C57BL/6 (BL6) and SJL/J (SJL) 
genetic backgrounds. Endogenous and knock-in Ig H chains can be readily identified 
serologically by their allotypes. C57BL/6 and SJL/J mice produce Ig of allotype b (Ighb), 
whereas the targeted Ig H gene locus in TH mice is derived from the strain 129/Sv, with 
allotype a (Igha) [31]. B cells from SJL or BL6 WT mice were mixed 1:1 with B cells from SJL or 
B6 TH mice (Figure 16 B). As expected, IgMa and IgMb expression on day 1 is similar in all 
groups. On day 8 IgMa and IgMb levels are dramatically decreased due to isotype switch.  
Detection of IgG1a and IgG1b was investigated but no signal was found after 8 days of culture 
suggesting that the available reagents are not suitable for flow cytometry (data not shown). 
Thus, detection of allotype for tracking B cell fate upon transfer seems only useful before 
isotype switch to IgG1 because IgM is downregulated after activation. Since B cell fate after 
transfer is unclear, a detection tool is needed that reliably labels B cells regardless of their 
differentiation and proliferation status. Therefore, the use of allelic markers for donor B cell 
detection after transfer was evaluated. B cells from heterozygous CD45.1/2 mice were 
cultured on 40LB cells (Figure 16 C). Expression of allelic markers remained stable over the 
entire culture period suggesting that allelic markers are suitable for long term tracking of 
highly proliferating iGB cells. 
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Figure 16: Testing of different reporter cells for tracking B cell fate after transfer. 
A) iGB culture of RFP and GFP B cells. RFP B cells derived from R&D mice (red bars) and GFP B cells derived from 
actin-GFP mice (green bars) were cultured for 8 days on 40LB cells in presence of IL-4 and IL-21. Expression of 
fluorescent proteins was measured at the indicated time points in live B cells via flow cytometry. B) Detection of 
different allotypes due to genetic backgrounds. WT B cells from BL6 or SJL mice were mixed 1:1 with TH B cells 
and cultured for 8 days on 40LB cells. BL6 WT/TH (black bars), their control (grey bars), SJL WT/TH (yellow bars) 
and their respective controls (orange bars) were analyzed for presence of IgMa+ and IgMb+ B cells (gated on 7AAD-
CD19+ CD138- cells) with flow cytometry. C) Detection of CD45.1 and 2 during iGB culture. B cells from CD45.1/2 
heterozygous mice were cultured for 8 days on 40LB cells and analyzed by flow cytometry. CD45.1+ and CD45.2+ 
cells were pre-gated on H2Kd- CD19+ CD138- cells. Representative data of 2 independent experiments with n=2 
mice is shown. Mean ± SEM. 
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3.3.4 Expansion of MOG-specific B cells in the iGB culture  
To study behavior of MOG-specific B cells from RR mice or immunized mice in the iGB culture, 
B cells from CLNs and spleen of sick RR and MOG/Alum immunized mice were cultured on 
40LB cells (Figure 17 A). In line with prior results from our laboratory, ex vivo not more than 
1% of B cells in RR mice and MOG-immunized mice were MOG-specific as they were able to 
bind a tetramerized mammalian MOG protein (MOGtet). Since MOG-specific B cells likely have 
been activated in vivo, we speculated that they expand even more in the iGB culture than 
naïve B cells. However, no enrichment or selective expansion of these MOG-specific B cells 
was detectable with MOGtet-staining after 8 days of iGB culture (Figure 17 A), indicating that 
either MOG-specific B cells have a similar expansion factor as naïve B cells, or that they 
cannot be detected anymore via MOGtet staining after iGB culture. 
To test whether MOG-specific B cells in the iGB culture are reliably detected via MOGtet 
staining, B cells from TH mice were mixed with B cells from WT BL6 mice (1:1) and cultured 
on 40LB cells (Figure 17 B). While on day 1 most of the MOG-specific B cells are detectable 
with MOG tetramer staining (about 40% of the 1:1 mixture), after 4 days MOGtet staining is 
slightly decreased compared to the control culture. Similar to the loss of signal observed for 
the fluorescent reporter proteins (see 4.1.3) MOG-specific B cells could not be detected via 
MOGtet staining anymore after 8 days of iGB culture. This phenomenon might be due to 
MOGtet binding better to IgM+ cells, where multiple immunoglobulins are linked together by 
strong covalent bonds than to IgG1+ cells with only two antigen binding sites. 
                            
 
Figure 17: Expansion of MOG-specific B cells in iGB cell culture. 
A) Expansion of B cells from sick RR or MOG immunized mice in iGB culture. B cells from sick RR mice, MOG/Alum 
immunized mice (iMOG) or SJL WT control mice were cultured for 8 days on 40LB cell in presence of IL-4 and IL-
21. B cells (H2Kd- CD19+ CD138- cells) were analyzed with flow cytometry for presence of MOGtet+ B cells. B) 
Detection of MOG specific TH B cells with MOGtet staining. B cells from BL6 WT and TH mice were mixed 1:1 and 
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cultured for 8 days on 40LB cells in presence of IL-4 and IL-21 (black bars) or without cytokines (grey bars). Mean 
± SEM from 2 independent experiments with n = 2 is shown. 
3.3.5 Selective expansion of MOG-specific B cells with the FAIS system 
As previously reported, not more than 1% of B cells in CLNs of RR mice are MOG-specific. 
Moreover, expansion of B cells from sick RR and MOG immunized mice did not result in 
enrichment of MOG-specific B cells during normal iGB culture. Therefore, a protocol to 
selectively expand MOG-specific B cells in the iGB culture was tested. In analogy to the 
selective expansion of HEL-specific B cells in iGB culture shown by Kitamura and colleagues 
[117], we created MOG-40LB cells and MOG-FasL cells for selective expansion of MOG-
specific B cells taking advantage of the fact that iGB cells are sensitive to Fas-induced cell 
death unless their antigen receptors receive a survival signal by their specific antigen (FAIS 
system) (Figure 18 A). MOG-40LB cells and MOG-FasL were created in our lab via viral 
transduction. Both cell lines express MOG, CD40L and BAFF (Figure 18 B). Antigen specific 
selection of MOG-specific B cells was performed as described previously for HEL [117]: First, 
B cells were expanded for 5 days on normal 40LB cells. Second, B cells were stimulated for 
6h on MOG-40LB cells. Third, B cells were plated on MOG-FasL cells for 8h for antigen-specific 
selection. In this step, only MOG-specific cells should be protected from Fas-FasL- induced 
cell death. Afterwards, B cells were purified and cultured for 4-6 days on 40LB cells for 
recovery. For these experiments B cells were either isolated from SJL/J mice immunized with 
rMOG, or B cells from TH mice were mixed at a ratio of 1:99 with cells from SJL WT mice and 
cultured under antigen-specific selection conditions (Figure 18 C-D). In the first 6 days B cells 
expanded up to 10 fold. As expected, during the selection procedure the majority of the B 
cells died. However, after 4-5 days recovery there was no evidence that MOG-specific B cells 
survived the selection process better than WT cells, since preferential expansion of MOG-
specific B cells at the end of the culture was not observed. In order to optimize the protocol 
for selective expansion of MOG-specific B cells, different culture conditions were tested (data 
not shown). After 4 or 6 days on 40LB cells, expanded iGB cells were either stimulated for 6h 
or overnight on MOG-40LB cells. Selection procedure was either performed on FasL or MOG-
FasL cells. To reduce stressful procedures for fragile iGB cells, purification steps before and 
after antigen stimulation were eliminated, and only purification after selection was 
performed to remove toxic FasL cells from the recovery culture. B cell stimulation on MOG-
40LB cells overnight showed slightly lower B cell expansion than stimulation for 6h. B cell 
selection on FasL versus MOG-FasL cells resulted in equally low numbers of surviving B cells. 
Removal of purification steps before and after antigen stimulation increased the overall 
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number of remaining B cells. However, none of these modifications selectively increased the 
survival/expansion of MOG-specific B cells. Furthermore, the difficulties to detect MOG-
specific B cells by MOGtet staining further complicated the interpretation of the results.  
It is possible, that the FAIS protocol is not applicable to all sorts of antigens characterized by 
very different BCR affinities and binding properties. Thus, being an autoantigen MOG 
probably has lower affinity than the foreign antigen HEL, which was used in the original FAIS 
protocol. To test this hypothesis, selective expansion of HEL-specific B cells as published 
before by Kitamura was tested. Splenic B cells from swHEL mice which are 90–95% HEL-
specific and can switch to all Ig isotypes [107] were mixed in a frequency of 15% or 50% with 
WT BL6 splenic B cells and selectively expanded with the FAIS system. Pure WT BL6 and pure 
HEL-specific B cells were used as negative and positive control as WT cells should not survive 
the selection process.  
Unfortunately, the selective expansion of HEL-specific B cells (Figure 18 E-F) was not 
reproducible in our hands. Additionally, HEL-specific B cell selection from HEL immunized 
mice was investigated (data not shown). WT BL6 mice were immunized with HEL protein, and 
after 3 weeks HEL-specific IgG titers were measured. Mice with high titers of HEL-specific 
antibodies were sacrificed and B cells from spleen and draining LNs were expanded in the 
iGB culture. However, again there was no enrichment of HEL-specific B cells after FAIS 
selection. 
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Figure 18: Selective expansion of antigen-specific cells in the FAIS system. 
A) BALB/c 3T3 fibroblasts were transfected with mouse CD40L and BAFF cDNA (40LB cells). Primary B cells are 
cultured with 40LB cells as feeder layer in the presence of IL-4 or IL-21. For antigen-specific B cell selection 40LB 
cells were first transduced with pSIREN-RetroQ-shFas vector and then Fas negative cells were further transduced 
with pMX-FasLIRES-hCD8 vector. Draft modified from [59] B) Schematic representation of antigen-specific 
selection protocol (FAIS). Purified B cells or whole splenocytes were cultured for 4 days on 40LB cells with IL-4 
and 2 days with IL-21. For antigen stimulation, B cells were cultured on MOG-40LB cells for 6h. Afterwards B cells 
were selected with MOG-FasL or FasL cells for 8h. B cells were purified by removal of FasL+ and H2Kd+ feeder cells 
and were allowed to recover on 40LB cells for 4-6 days. C) Flow cytometry analysis of MOG-40LB (upper panel) 
and MOG-FasL (lower panel) cells. MOG-40LB and MOG-FasL cells (blue lines) were tested for expression of MOG 
(left panel) and FasL (right panel) in comparison to regular 40LB cells (red lines) and unstained control cells (yellow 
lines). D) Selection of MOG-specific B cells from rMOG immunized SJL/J mice, as well as B cells from TH SJL mice 
mixed 1:99 with WT cells. Graph shows B cell numbers in the different phases of the FAIS protocol. E) Number of 
surviving B cells after 5 days recovery. F) Selection of HEL-specific B cells from swHEL mice mixed with WT BL6 
cells. G) Number of surviving B cells after 5 days recovery. Mean ± SEM from 3 independent experiments with n 
≥ 2 mice is shown.  
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3.3.6 Adoptive transfer of TH or WT iGB cells as a tool for B cell studies 
To study function, properties and pathogenic potential of MOG-specific iGB cells adoptive 
transfer of WT and TH iGB cells was performed. 2D2 mice [30], which carry a transgenic MOG-
specific TCR and in which the incidence of spontaneous EAE is very low (<5%), were used as 
recipients to test whether transfer of MOG-specific iGB cells can trigger development of 
disease. To be able to track B cells after transfer, splenocytes were either isolated from actin-
GFP or CD45.1/2 mice crossed with TH mice. Whole splenocytes were cultured for 4 days in 
iGB culture with IL-4, stimulated with or without rMOG for 1-2 h, and then injected. Mice 
were observed at least 16-18 days post transfer or, in case of disease development, analyzed 
2 days after first showing clinical signs of EAE. At the time of transfer WT and TH x GFP iGB 
cells showed a GC phenotype after 4 days of culture, and the majority of B cells were still 
IgM+ (Figure 19 A).  
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Figure 19: Phenotype of TH and WT iGB cells before and after transfer into 2D2 mice. 
Actin-GFP and GFPxTH splenocytes were cultured for 4 days on 40LB feeder cells with IL-4. After iGB culture, cells 
were washed and around 20x106 iGB cells were injected into 2D2 mice. Mice were monitored for development 
of EAE and sacrificed at the latest 18 days post transfer. A) Gating strategy and phenotype of TH and WT iGB cells 
in culture at the time of transfer. GFP+ B cells (H2Kd- CD19+ GFP+) were analyzed for expression of IgM, IgG1, FAS, 
GL7, PNA and CD38. B) Gating strategy and phenotype of transferred GFP+ cells in recipient mice 18 days post 
transfer. GFP+ B cells (7AAD- CD19+ GFP+) were analyzed for expression of IgMa, IgG1, FAS, GL7, PNA and CD38. C) 
Frequency of transferred GFP+ iGB cells in spleen, inguinal, mesenteric and cervical lymph nodes and CNS. CD11b- 
CD4- CD19+ cells were analyzed for expression of GFP+. Mean ± SEM from >3 independent experiments with WT 
iGB n=8, TH iGB n=17 are shown. 
After transfer, IgMa expression was significantly higher in mice that received MOG-stimulated 
TH iGB cells compared to TH iGB cells without pre-stimulation, and not detectable in 
recipients of WT iGB cells, as expected (Figure 20).  IgG1 expression was low in all mice, 
however, significantly increased in spleen and iLNs of recipients of MOG-stimulated TH iGB 
cells compared to recipients of WT iGB and non-stimulated TH iGB cells. Additionally, IgG1 
expression in transferred cells in the CNS was slightly higher than in other organs especially 
in TH iGB recipients, while IgM expression in the CNS was markedly reduced compared to the 
periphery. As described by Kitamura, after transfer WT iGB cells still expressed moderate 
levels of Fas but had downregulated GL7 (Figure 19B and 20). However, recipients of TH iGB 
cells showed significantly higher FAS expression compared to WT iGB cells. All transferred 
cells still expressed CD38 but were negative for PNA. Thus, after transfer into recipient mice 
B cells displayed an activated/memory phenotype rather than a germinal center B cell 
phenotype. After 16-18 days GFP+ cells were equally distributed between inguinal, 
mesenteric and cervical lymph nodes with a slight but not significant enrichment in spleen 
(Figure 19 C). No preferential accumulation of GFP+ B cells was visible in any of the peripheral 
organs. Among CNS infiltrating B cells, the frequency of GFP+ B cells was increased compared 
to peripheral organs, however, the overall frequency of CNS-infiltrating B cells compared to 
infiltrating T cells was very low, indicating that transferred B cells may not play a major role 
in the inflammatory processes in the CNS in this model. Phenotyping of transferred cells 
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indicated that TH iGB cells are more activated showing increased FAS expression in all organs 
(Figure 20). 
 
Figure 20: Phenotyping of transferred iGB cells in different organs. 
Characterization of WT, TH and TH iGB cells without MOG before transfer (in culture) and re-isolated from spleen, 
inguinal, mesenteric and cervical lymph nodes as well as CNS of recipient mice 16-18 days after transfer. Cells 
were gated on size, 7AAD- or CD4-, CD11b- or CD138-, CD19+, GFP+ cells. Mean ± SEM from >3 independent 
experiments with WT iGB n=9, TH iGB n=12 and TH iGB cells without rMOG n=7 are shown. *P<0.05, 
***P<0.01***P<0.001, t-test for IgMa or 1-way ANOVA, Kruskal Wallis test – Dunn’s multiple comparison test. 
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3.3.7 TH iGB cells trigger development of EAE in 2D2 recipient mice 
Importantly, transfer of TH iGB cells into 2D2 mice resulted in development of EAE with high 
severity in about 50-60% of recipients between 7-11 days post transfer, whereas recipients 
of WT iGB cells remained healthy (Figure 21 A and B). Interestingly, recipients of MOG-pulsed 
TH iGB cells developed EAE with similar incidence and mean maximum scores as recipients 
of unpulsed TH iGB cells, indicating that provision of exogenous MOG antigen is not required 
for the pathogenicity of TH iGB cells. Overall, the incidence of EAE in 2D2 mice after transfer 
of TH iGB cells was increased dramatically above the rate of spontaneous EAE in 2D2 mice 
which typically lies below 5% [30]. Serum ELISA analysis from 2D2 recipient mice showed high 
titers of MOG-specific IgMa and IgG1a in recipients of TH iGB cells (Figure 21 C). Taken 
together, TH iGB cells are able to induce EAE in 2D2 mice, even without stimulation by 
autoantigen and can be used as a new tool to study the role of B cells in initiation of EAE.  
 
Figure 21: Adoptive transfer of TH iGB cells triggers development of EAE in 2D2 mice 
A) EAE incidence in 2D2 mice after transfer of either WT iGB cells, or TH iGB cells stimulated with or without MOG. 
B) Mean maximum EAE score in 2D2 recipient mice. Only sick mice were included in the graph. C) Presence of 
MOG-specific IgMa and IgG1a in the serum of 2D2 recipient mice was determined by ELISA. Mean ± SEM from >3 
independent experiments with WT iGB recipients n=8, TH iGB recipients n=12 and TH iGB cells without rMOG 
recipients n=8 are shown. 
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4 DISCUSSION 
4.1 Antigen transport 
According to the literature and latest findings [68, 78, 81], recruitment of B cells through 
auto-antigen transport may play an important role in the development of EAE. Therefore, 
drainage pathways of auto-antigens via cells or exosomes from the CNS to CLNs were 
investigated. 
After intrathecal injection of dextran-FITC, dextran-Alexa Fluor 488 and 647, dextran positive 
leukocytes were detected in CLNs indicating a direct drainage pathway from the CNS to the 
regional lymph system (Figure 2). However, further studies with intrathecal injection of MOG-
FITC could not confirm translocation of auto-antigen to regional lymph nodes (Figure 3). 
Dextran-FITC (70 KDa) is smaller in size than MOG-FITC (110 kDa), which might alter migration 
properties of the soluble molecules. Thus, mammalian MOG may be too big to pass from CNS 
to regional lymph nodes without degradation. In an alternative approach, tracking of CNS 
antigen during the development of EAE using PLP-GFP reporter mice (Figure 4) was tested, 
but almost no GFP+ lymphocytes or myeloid cells were found in CLNs or other organs. Positive 
staining for PLP, MBP and MOG in the CLNs of sick RR mice would support the hypothesis 
that auto-antigens are transported from CNS to CLNs. However, positive staining was not 
only detected in the CLNs of sick RR mice, but also in the CLNs of healthy NTLs (Figure 5 A-C) 
and - for MOG - in MOG-deficient mice (Figure 6). To exclude unspecific Fc receptor binding, 
staining with anti-MOG F(ab)2 antibody was performed (Figure 5 D). Although the anti-MOG 
F(ab)2 antibody detected MOG in the CNS, positive staining was no longer detectable in the 
CLNs of sick RR mice and NTLs. These data suggest that the regular MOG-specific antibody 
binds unspecifically to Fc receptors on macrophages. Concordantly, MOG staining did not 
colocalize with B220 and CD4 but with the macrophage markers CD11b/CD68 (Figure 6). 
Given that no PLP-GFP signal was detectable in the CLNs using reporter mice, it is likely that 
the observed positive signals for PLP and MBP are also false positive signals caused by 
unspecific capture of the staining antibodies via Fc receptors on macrophages.  
Immunohistological analysis of CLNs of RR mice and FACS analysis of CLNs of PLP-GFP mice 
with EAE suggest that myelin antigens are either not transported to CLNs of sick mice or are 
no longer detectable due to degradation of the epitopes recognized by the antibodies: thus, 
it is possible, that by the time the auto-antigens reach the CLNs their epitopes are already 
destroyed by antigen-processing in APCs and can therefore no longer be detected by 
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antibodies. Additionally, unspecific staining of PLP and MBP may not only be due to Fc 
receptor binding but also due to the recognition of other isoforms expressed in the periphery 
[125-127]. Thus, the shorter isoform of PLP, DM20, has been detected in the periphery in 
thymic cortical epithelium [127], and Golli-MBP isoforms were shown to be expressed in fetal 
thymus and spleen [125]. Therefore, it is possible that these isoforms also exist in CLNs where 
they may be detected by the antibodies used here. In contrast to MBP and PLP, expression 
of MOG isoforms outside the CNS has not been observed [126], and in line with this, the anti-
MOG F(ab)2 antibody did not stain cells in CLNs. These data suggest that the positive signal 
for myelin antigens in CLNs of RR mice is due to unspecific binding of antibodies to Fc 
receptors on macrophages, and that myelin antigens are not transported as whole proteins 
from the CNS to CLNs during EAE. However, presence of processed myelin antigens 
(fragments/peptides) in CLNs cannot be excluded, and thus it is still possible that processed 
myelin antigens are transported to CLNs and presented to autoreactive lymphocytes. Future 
studies should concentrate on using proteomics as a tool for myelin antigen detection as it is 
much more sensitive for small amounts of protein fragments. 
Several studies have analyzed tissues from MS patients as well as EAE tissues (CSF, spinal 
cord and brain), however the only myelin protein found to be significantly increased in CSF 
of MS patients and aEAE in all proteomic studies was MBP, probably because it is the most 
prominent protein of the myelin sheath [128]. There are no proteomic studies analyzing CLNs 
in EAE, but technically, it is possible to perform tissue-based proteomics. Nevertheless, there 
is still a detection limit for proteins/peptides which might be too low to detect small amounts 
of myelin proteins/peptides in early disease stage of sEAE. In addition, since myelin proteins 
may only be transiently present in CLNs of RR mice, identifying the right time point for a 
proteomic analysis would be crucial and challenging in RR mice given the late onset of 
spontaneous disease after 3-4 months of age. In that regard, 2D2xTH mice might be the 
better option for proteomic analysis of CLNs due to the earlier onset of disease around 6 
weeks of age.  
Exosomes can modulate immune functions, affect communication between cells and are able 
to transport various proteins [82, 84, 85, 87]. Since neuronal antigens have been found in 
CLNs of marmoset monkeys with active EAE and in patients with MS [80, 81], one hypothesis 
is that exosomes function as a transport system for autoantigens between CNS and CLNs. To 
be able to test this hypothesis, first a method for the isolation and characterization of 
microvesicles from different cell sources was established (Figure 7-8). Isolated nanoparticles 
showed the typical size and shape of exosomes and expressed exosome markers like Alix, 
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Tsg101, CD63, and CD9, as well as corresponding cell type markers. Furthermore, exosomes 
isolated from EL4-MOG and H2M BMDCs were able to carry MOG on their surface and even 
showed an enrichment of MOG compared to their celllular origin (Figure 10 B, D). As shown 
by previous reports, exosomes can perform cell-independent microRNA (miRNA) biogenesis 
and are an enriched source of mRNAs [129, 130]. Thus, enrichment of MOG mRNA in 
exosomes compared to their cellular origin is possible. These data indicate that exosomes 
from EL4 cells and BMDCs can be successfully isolated, and that exosomes derived from EL4-
MOG cells or H2M BMDCs have the potential to transport MOG and present it on the surface. 
As exosomes can stimulate T cells by direct or indirect antigen presentation [131, 132], in 
vitro T cell activation assays with MOG enriched exosomes could be performed. To determine 
whether T cells are activated directly through antigen presentation on exosomes or indirectly 
by transfer of exosomal antigen to APCs, different experiments have to be performed: MOG-
containing exosomes could be directly co-cultured with MOG-specific T cells from RR mice or 
OSE mice. Alternatively, B cell/DCs could be co-cultured with exosomes and then T cells could 
be added later to test whether exosomal MOG is transferred to APCs, which in turn present 
it to T cells. Qazi et al. showed that B cells are required for exosomal T cell activation, as B 
cell signaling-deficient mice show decreased splenocyte proliferation in response to 
ovalbumin loaded exosomes [133]. Considering these data, it is possible that exosomes 
activate T cells by antigen–MHC complex transfer to B cells leading to indirect antigen 
presentation. Thus, exosomes shed from EL-4 MOG cells injected directly into RR mice may 
accelerate and exacerbate EAE induction. This would be the first clue that exosomes are a 
potential factor in myelin antigen transport and activation of autoreactive T cells in 
spontaneous EAE. 
However, exosome studies in mice have several limitations: firstly, isolation of exosomes is 
only feasible from fluids like cell culture supernatant, urine, blood and CSF. There are no 
reports confirming successful exosome isolation from tissue. Secondly, determining the 
relevance of exosomes as a transportation system for myelin antigens in vivo would require 
isolation of exosomes from the CSF of sick RR mice. However, the amount of CSF that can be 
obtained from sick mice (2-5 µl) is not sufficient for reliable characterization or meaningful 
functional analysis or transfer of exosomes. Thirdly, intravenous injection of exosomes to 
mice is lethal due to aggregation of vesicles and blocking of capillaries (personal 
communication with Dr. Mikael Simons). Taken together, it is currently not feasible to show 
the physiological role of exosomes as a transportation system for myelin antigens and related 
B cell or T cell activation in RR mice.  
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4.2 B cell activation studies in the intestine 
According to recent findings, recruitment of MOG-specific B cells may be an important factor 
in development of EAE. RR mice are fully protected from spontaneous EAE, when housed 
under germ-free conditions. Furthermore, MOG-specific B cells get recruited to CLN of these 
mice suggesting that the microbiota and the autoantigen cooperate somehow for the 
generation of a pathogenic autoimmune response in this model [68]. As we were not able to 
demonstrate autoantigen transport of MOG from CNS to CLNs, an alternative possibility is 
that autoreactive B cells are activated by a microbal foreign protein mimicking MOG in the 
intestine first and migrate to CLNs afterwards. To study whether B cells are activated in the 
gut by molecular mimicry, transfer studies with MOG-specific B cells into RR recipient mice 
were planned to determine the B cell activation status in different intestinal segments, as 
well as in other organs. To establish the experimental system, transfer experiments with 
actin-GFP reporter cells were performed but revealed several limitations.  
First of all, even transfer of 25 x 106 splenocytes or 10 x 106 purified B cells from actin-GFP 
mice resulted in very low frequencies of GFP+ cells in intestinal segments (Figure 9). To draw 
reliable conclusions regarding activation of transferred B cells in different segments of the 
intestine, transferring a high number of B cells per mouse is necessary. However, since the 
actin-GFP transgene is lethal in homozygotic embryos, heterozygous mice have to be used in 
which not all cells are actin-GFP+. Therefore, many mice are required to provide enough B 
cells to perform transfer experiments. Furthermore, GFP signal is lost during the intracellular 
staining procedure (Figure 10) which is necessary to measure intracellular markers such as 
cytokines and transcription factors und thereby characterize the transferred B cells. Even 
with optimized staining conditions approximately 60 % of the signal was lost during fixation, 
permeabilization and staining. To overcome staining procedure limitations, GFP+ B cells could 
be isolated and sorted from the intestinal segments and expression of intracellular markers 
like cytokines and transcription factors could be determined on the RNA level. 
One reason for the low overall frequencies and persistence of transferred B cells could be 
their activation status. When B cells do not bind their antigen or receive some other 
activation/survival signal for example via CD40, IL-4 or IL-21 they die easily. B cells need T cell 
help for their survival, proliferation and differentiation [134]. In future studies, B cells could 
be either pre-activated with antigen or cytokines before transfer, or they could be 
transferred in combination with T cells of the same antigen specificity. This would of course 
mask natural B cell activation in vivo, which we would like to determine, but at least migration 
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patterns could still be investigated. Furthermore, B cells have no reason to migrate from the 
intestine to CLNs or CNS when they do not encounter antigen. Another option to study 
activation of autoreactive B cells in the intestine would be to provide a strong controlled 
stimulus by gavaging of MOG protein to host mice, especially if B cell activation stimuli 
provided by bacterial proteins or metabolites in the gut are too low to see an effect. This 
approach could be used to study migration of activated MOG-reactive B cells from the gut to 
other locations.  
Low B cell frequencies were probably a result of poor B cell survival in an immunocompetent 
host that does not provide much antigen or cytokine stimuli for their survival, proliferation 
and differentiation [134]. An option to overcome this is to use R&D mice carrying RFP and 
the human DTR on their B cells, which allows for depletion of B cells via administration of 
diphtheria toxin. Therefore, a niche for transferred B cells could be created allowing survival 
of these cells. Another nice feature of these mice is that host B cells are easy to distinguish 
from transferred GFP+ B cells by RFP expression. However, in this experimental set-up it might 
be difficult to differentiate between B cell proliferation/activation caused by lymphopenia 
versus recognition of auto-antigen.  
4.3 New tool for B cell studies in EAE 
Several limitations and difficulties have hindered meaningful studies to investigate the 
recruitment, activation and properties of antigen-specific B cells in EAE. To overcome the 
limitations posed by low frequencies of autoantigen-specific B cells and to be able to 
characterize and manipulate different B cell populations a new culture system for B cell 
expansion and selection was established.  
The iGB cell culture system from Kitamura et al. [116] was successfully adapted for our 
purposes and needs. B cells were expanded and characterized from BL6, SJL/J, R&D SJL/J, 
actin-GFP BL6 and RR mice (Figure 12). B cells from all strains expanded 8-10 fold in the 
primary culture and about 300 fold in the secondary culture. Expansion rates were similar in 
BL6 and SJL/J mice. B cells were also characterized with flow cytometry. They showed a clear 
GC phenotype and isotype switch from IgM to IgG1 in presence of IL-21 (Figure 13). Culture 
conditions were miniaturized to optimize expansion of low B cell numbers from different 
organs (Figure 14). Moreover, culture of fluorescently labeled B cells from R&D SJL/J and 
actin-GFP mice for later transfer experiments was tested. Unfortunately, RFP signal from R&D 
SJL mice decreased dramatically during iGB culture; however, actin-GFP remained reasonably 
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bright during iGB culture and proved suitable for transfer experiments (Figure 16 and Figure 
19). Additionally, the congenic markers CD45.1 and CD45.2 can be used for tracking B cells 
during iGB culture and in future transfer experiments. In order to track MOG-specific B cells, 
MOG tetramer staining both on B cells from MOG-immunized mice as well as on B cells from 
TH mice during iGB culture was performed. Unfortunately, MOG tetramer staining also 
decreased over the culture period (Figure 16). This could be due to MOGtet binding better to 
IgM+ than to IgG1+ cells. To find a solution for detection of B cells after transfer, allotype 
specific markers for TH B cell detection, which reliably differentiated TH B cells from WT B 
cells were tested. However, allotype specific marker detection was only established for IgMa 
and thus only useful for transfer experiments of primary culture iGB cells before isotype 
switch.  
Cell culture conditions were modified to avoid loss of B cells during isolation procedure. Thus, 
whole splenocytes can be plated on 40LB cells without prior B cell isolation. Other cell types 
including T cells, macrophages and dendritic cells largely died during iGB culture and did not 
influence B cell expansion or differentiation (Figure 15). Culture of CNS-derived B cells from 
a sick mouse was successfully performed and showed expansion and differentiation to iGB 
cells. Collectively, the iGB cell culture system is a useful tool to expand and differentiate low 
numbers of B cells from different organs and actin-GFP or congenic markers are the most 
promising candidates to track B cells in adoptive transfer experiments. 
Additionally, we tried to establish a FAIS cell culture system for selective expansion of MOG-
specific B cells in order to study the rare MOG-specific B cells emerging from the endogenous 
repertoire in RR mice. For this purpose MOG-40LB and MOG-FasL feeder cells were created 
(Figure 19). In contrast to published data selective expansion of Ag-specific B cells was not 
successful. Different culture conditions were tested in order to optimize Ag-specific B cell 
expansion, but the modifications did not significantly improve survival/expansion of selected 
B cells. MOG-specific B cells are either not selected and do not recover after the B cell 
selection step or are not any longer detectable by MOG tetramer due to downregulation of 
the BCR or reduced binding affinity of the isotype-switched BCR to MOG tetramer. As a prove 
of principle selective expansion of HEL-specific B cells was investigated which was already 
published by Kitamura [117] (Figure 18). However, published results were not reproducible 
in our hands and HEL-specific B cells seemed to not survive or recover better than WT cells. 
One reason why selective expansion of MOG-specific B cells failed could be that selection 
only works for certain antigens depending on protein size, epitope and binding affinity. 
However, also expansion of HEL-specific B cells failed and therefore the reason could be that 
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cells are extremely sensitive to culture conditions such as supplemented growth factors, type 
of medium and cytokines. Therefore, it should be considered to standardize culture 
conditions from the published protocol. Taken together, adaptation of the FAIS system for 
different antigens is not trivial and seems to be very sensitive to external factors. Thus, we 
could not utilize this system to expand and characterize MOG-specific B cells.   
Another approach to expand and characterize MOG-specific B cells is to do transcriptomics. 
As culture of CNS derived B cells from a sick mouse was successfull, clones of these B cells 
could be expanded with the new iGB culture tool. B cells could be isolated from the CNS of 
sick RR mice, single sorted into 96 well plates with feeder cells and after clonal expansion 
analyzed for their antigen titers. Clones with high titers of MOG-specific antibodies could be 
then further analyzed with transcriptomics for their target epitopes. This method could 
provide insights into heterogenicity of B cell auto-antigens. Dornmair et al. were able to 
combine biochemical analysis, proteomics, and transcriptomics to molecularly characterize 
distinct OCB antibodies of MS patients [61]. They characterized three auto-antigens, 
however, all of them were ubiquitous intracellular proteins, not specific to brain tissue. The 
combination of the expansion of single clones in iGB cell culture as well as the tools from 
Dornmair et al. could help to overcome the limitation of the FAIS culture system.  
Next, the iGB cell culture system was used as a tool to expand/manipulate TH B cells in vitro 
and transfer them to recipient mice. Firstly, we wanted to test if B cell activation in iGB 
culture leads to a better survival upon transfer compared to naïve B cells used  in our B cell 
activation studies in the intestine. Secondly, we wanted to analyze and characterise role, 
function and properties of MOG-specific B cells in the initiation of EAE instead of focusing on 
expansion of MOG-specific B cells in vitro. To do so, adoptive transfer of actin-GFP WT and 
TH iGB cells into 2D2 recipient mice was performed (Figure 21). The adoptive transfer of TH 
B cells into 2D2 mice was chosen because in contrast to RR mice the incidence of spontaneous 
EAE in single transgenic 2D2 mice is close to 0%, and previous studies suggest a prominent 
role for B cells as APCs in this model [32, 33, 135]. Therefore, day 4 iGB cells were transferred 
assuming they retain good APC function. TH iGB cells were able to induce EAE in about 60% 
of 2D2 recipient mice even without pre-stimulation with rMOG. These data suggest that 
exogenous MOG is not required for induction of spontaneous EAE, since adoptive transfer of 
TH iGB cells stimulated with or without MOG induced EAE with similar incidence and severity. 
In recipients of MOG-stimulated TH iGB cells the frequency of IgMa-positive cells among 
transferred cells was reduced, while the frequency of IgG1-positive cells in spleen and iLNs 
was increased compared to recipients of unstimulated TH iGB cells (Figure 20). These data 
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could indicate that stimulation with MOG before transfer leads to a higher fraction of 
surviving isotype-switched TH B cells in the host. FAS expression in transferred cells in 
recipients of unstimulated TH iGB cells was significantly higher than in recipients of WT iGB 
cells and trending higher than in recipients of MOG-stimulated TH iGB cells suggesting that 
transferred TH iGB cells maintain a higher activation status upon in vivo transfer, which may 
result from interaction with MOG-specific T cells in 2D2 recipients. Moreover, TH and WT iGB 
cells were equally distributed in spleen, iLNs, mLNs, CLNs and CNS. No enrichment of iGB cells 
in mLNs was detected suggesting that B cells do not preferentially migrate to the intestine. 
Therefore, there is no indication for B cell activation in the intestine at least in the 2D2 mouse; 
however, manipulation of B cells in vitro before transfer might also conceal this 
phenomenon. 
These data suggest that exogenous MOG is not required for induction of EAE. Recipients of 
TH iGB cells showed increased FAS expression on transferred cells compared to recipients of 
WT iGB cells indicating higher activation status. The reason for this may be active cooperation 
between 2D2 T and TH iGB cells, as observed in the OSE model: the presence of MOG-specific 
T cells led to massive production of MOG-specific IgG1 antibody, and MOG-specific B cells 
also enhanced MOG-specific T cell proliferation and activation [32, 34]. One argument why 
pre-stimulation of MOG is not necessary could be that TH iGB cells are able to find and 
present endogenous MOG and that APC function of transferred TH iGB cells is of major 
importance in this setting. 2D2 mice are prone to develop optic neuritis and may also have 
subclinical inflammation in the CNS [30] This could be the reason why the BBB in 2D2 is more 
leaky compared to WT mice and so, transferred B cells may have access to endogenous MOG 
by entering the CNS or by antigen leaking from optic nerve/CNS to the periphery. This would 
be in line with several reports showing that B cell antigen presentation is sufficient to drive 
neuroinflammation in EAE: thus, a recent study demonstrated that increasing the precursor 
frequency of MOG-specific B cells but not the addition of soluble MOG-specific antibody is 
sufficient to drive EAE in mice expressing MHC class II only in B cells [136]. Additionally, 
another group showed that MHC class II-dependent B cell APC function is required for 
induction of CNS autoimmunity independent of myelin-specific antibodies [137]. They 
demonstrate that in models that require participation of B cells their cellular function is 
necessary and sufficient for induction of CNS autoimmunity. Moreover, it was shown that B 
cells promote induction of EAE by facilitating reactivation of T cells in the CNS, and that B 
cells are the predominant MHC class II-expressing subset in the naïve CNS, and they 
constitutively express proinflammatory cytokines [138]. On the other hand, MOG-specific 
IgMa and IgG1a were also detected in the serum of our TH iGB cell recipients (Figure 21), and 
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thus at present we cannot exclude that antibodies also contribute to pathogenesis in our 
model. Supporting this idea, it was recently shown that myelin-reactive antibodies are 
capable of initiating an encephalitogenic immune response by targeting endogenous CNS 
antigen to otherwise inert myeloid APC [139]. Kinzel et al. demonstrated that constitutive 
production of Ab against MOG was sufficient to promote EAE even in the absence of B cells, 
when mice carried MOG-specific T cells. In line with that, Flach et al. found that myelin-
specific antibodies produced by autoreactive B cells after activation in the periphery diffused 
into the CNS together with the first invading pathogenic T cells [135].  
Thus, in our model it remains to be determined whether transferred B cells function primarily 
as APCs and cytokine producers, or whether their function as antibody producers is crucial in 
the initiation of EAE. The successful establishment of iGB cell differentiation and expansion 
provides opportunities to test this, for example one can compare adoptive transfer of TH 
memory iGB cells vs. TH plasmablasts, to determine whether APC function or antibody 
production is more important for induction of EAE. If 2D2 recipients of TH plasmablasts 
develop no or attenuated EAE, MOG autoantibodies might not be essential in the initiation 
of EAE development but may play a role only in later stages of the disease. This would be in 
line with recent studies of B cell depletion in relapsing-remitting MS, where treatment with 
rituximab reduced inflammatory brain lesions and clinical relapses even though plasmablasts 
are not depleted by this treatment [70]. If the APC-function of the transferred TH iGB cells 
proves to be essential for initiation of disease, further experiments could be performed to 
identify the molecular players contributing to B cell pathogenicity during antigen 
presentation. Here, cytokines are important candidates since they may directly influence 
polarization of the interacting T cells during antigen presentation. Thus, for example IFN-γ 
produced by B cells could enhance Th1 polarization, while IL-6 could enhance Th17 
differentiation. In addition, B cells can also produce pro-inflammatory cytokines acting on 
non-T cells including GM-CSF and LT, as well as anti-inflammatory cytokines like IL-10. 
Importantly, due to the high proliferation rates in the iGB culture system TH B cells could be 
manipulated via retroviral transduction to express different pro- or anti-inflammatory 
cytokines like LT-α, GM-CSF, IFN-γ or IL-10. Such an approach could provide valuable insight 
into effector B cell functions required for initiation of EAE development (Figure 23).  
B cell aggregates reminiscent of tertiary lymphoid organs (TLOs) were discovered in the 
meninges of MS patients, leading to the hypothesis that differentiation and maturation of 
auto-pathogenic B and T cells may also occur inside the CNS [51]. It has been shown that 
Th17 and LT- derived signals initiate formation of TLOs within the brain meninges [140, 141]. 
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B cells can support the normal development and maintenance of lymphoid structures and 
ectopic follicles [142]. In addition, B cells can form ectopic lymphoid follicle-like structures 
during chronic inflammatory conditions [143-145]. Increased expression of LT was detected 
in the SJL-immunization model at onset and upon relapses, and neutralization of LT 
decreased expression of the B cell attracting chemokine CXCL13 in the CNS [146], however, 
the cellular source of LT was not identified here. Considering that LT α1β2 expression on B 
cells is required for FDC activation during GC responses [147], it is possible that expression of 
LT-α by B cells also plays an important role in shaping the proinflammatory mileu during TLO 
formation and thereby contribute to B cell pathogenicity during EAE.  
Lately, a proinflammatory GM-CSF expressing human memory B cell subset was described, 
which is increased in frequency and more readily induced in MS patients compared to healthy 
controls [62]. GM-CSF expressing B cells efficiently activated myeloid cells in vitro, and B cell 
depletion therapy resulted in decreased proinflammatory myeloid responses of MS patients 
in vivo. A signal transducer and activator of transcription 5 (STAT5) - and STAT6-dependent 
mechanism was required for B cell GM-CSF production and reciprocally regulated the 
generation of regulatory IL-10 expressing B cells. Thus, balance between effector and 
regulatory B cells seems to be important for development of MS and could also be relevant 
in different stages of spontaneous EAE.  
In 2014, Bao et al. identified IFN-ƴ producing innate B cells [148]. Another group showed one 
year later that B cells expressing IFN-y suppress Treg-cell differentation and promote 
autoimmune experimental arthritis [149]. Furthermore, Lees et al. showed that regional CNS 
responses to IFN-ƴ determine lesion localization patterns during EAE pathogenesis [150]. 
Moreover, IFN-β has been used successfully to treat MS [151, 152] reducing exacerbations in 
relapsing-remitting MS, whereas IFN-ƴ provokes acute relapses [153]. Sosa et al. showed that 
IFN-ƴ ameliorates EAE by limiting myelin lipid peroxidation [154]. Using mice deficient for 
IFN-γ or IFN-γR or treating mice with neutralizing IFN-γ mAb, they found that the number of 
APCs containing myelin Ag in the CNS of mice with EAE was decreased, despite significantly 
more severe clinical disease, suggesting a previously unrecognized role for IFN-γ in 
controlling the disease process via modulating myelin Ag scavenging in the CNS. 
Unfortunately, they have not investigated the role of B cells in this process. Thus, it would be 
interesting to test the role of IFN-ƴ expressing B cells during spontaneous EAE.  
As mentioned before, dysregulation between effector and regulatory B cells might be 
important in the initiation of EAE. CD20 antibody-mediated B cell depletion before EAE 
induction resulted in exacerbated disease symptoms and increased encephalitogenic T cell 
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influx into the CNS [66]. Additionally, some patients treated with rituximab developed 
psoriasis, and a patient suffering from ulcerative colitis developed a severe exacerbation of 
the disease upon rituximab treatment, which coincided with elimination of regulatory IL-10-
producing B cells in the intestinal mucosa [155, 156]. Without IL-10, mice are not able to 
recover from EAE [157]. Thus, the therapeutic effect of B cell depletion for the treatment of 
autoimmunity may depend on the relative contributions and the timing of these opposing B 
cell activities during the course of disease initiation and pathogenesis. Therefore, the impact 
of regulatory IL-10 overexpressing B cells in EAE should be investigated. 
Overall, different B cell functions may be important during different stages of EAE. Thus, it 
should be considered at what time point which manipulated B cells and cytokines could play 
a role. It would be also interesting to investigate if IL-10 producing B cells could suppress 
pathogenic effects of B cells during initiation phase by transferring them in parallel with LT, 
GM-CSF or IFN-ƴ producing B cells. Furthermore, adoptive transfer of regulatory B cells could 
be performed in RR mice to determine if IL-10 producing B cells could delay onset or 
completely protect mice from spontaneous disease.  
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Figure 22: Schematic representation of future experiments 
Comparison of adoptive transfer of TH memory iGB cells and TH plasmablasts to study importance of APC-function 
versus production of auto-antibodies in initiation of disease (top.) Manipulation of TH iGB cells with retroviral 
transduction to express either pro-inflammatory cytokines such as GM-CSF, or anti-inflammatory cytokines such 
as IL-10 to study their role as effector or regulatory cells in EAE (created by Bettina Martin). 
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5 CONCLUSION 
The aim of this study was to investigate the activation and pathogenic potential of MOG-
specific B cells during development of spontaneous EAE. First, antigen transport and priming 
of autoreactive B cells was investigated by studying CNS drainage pathways, detection of 
auto-antigens transported from the CNS to CLNs and by studying exosomes as a potential 
transport system. Second, B cell activation in the instestine and recruitment to CLNs were 
studied via B cell transfer experiments. Due to several methodological limitations, presence 
of myelin auto-antigens in CNS regional LNs could not be unequivocally demonstrated 
neither by translocation of fluorescently labeled myelin proteins from CNS to CLNs in RR 
mice, nor by fluorescent PLP fusion protein in actively induced EAE, nor by direct 
immunohistochemical staining of myelin proteins in CLNs. Furthermore, investigating the 
role of exosomes as a transportation and B cell activation vehicle were difficult due to missing 
methods to show physiological relevance of myelin containing exosomes in development of 
EAE. Therefore, we next investigated potential B cell activation by myelin mimicking proteins 
on microbes in the intestine via transfer of GFP B cells. However, since transfer of GFP B cells 
did not show enrichment of B cells in intestine or mLNs, and since meaningful analysis was 
hindered by very low B cell frequencies presumably due to poor survival of transferred B 
cells, a new B cell culture system allowing expansion and differentiation of primary B cells 
was established [116]. In this third part of the thesis we could show that the iGB cell culture 
system is a useful tool to expand and differentiate low numbers of B cells from different 
organs and actin-GFP or congenic markers are suitable for tracking B cells in adoptive transfer 
experiments. Furthermore, we could demonstrate for the first time, that MOG-specific TH 
iGB cells can be succesfully transferred into 2D2 mice and are able to induce EAE in about 
60% of 2D2 recipient mice even without pre-stimulation with rMOG. These data suggest that 
exogenous MOG is not required for induction of EAE. Recipients of TH iGB cells showed 
increased FAS expression on transferred cells compared to recipients of WT iGB cells 
indicating higher activation status. The reason for this may be active cooperation between 
2D2 T and TH iGB cells, as observed in the OSE model, where the presence of MOG-specific 
T cells led to massive production of MOG-specific IgG1 antibody, and MOG-specific B cells 
also enhanced MOG-specific T cell proliferation and activation [32, 33]. While the final trigger 
of disease development is difficult to determine in the OSE mouse due to the simultaneous 
presence and development of MOG-specific B and T cells, our transfer of MOG-specific iGB 
cells into 2D2 recipients clearly shows that B cells have the capacity to deliver the necessary 
signals that trigger development of disease. The exact nature of these signals can now be 
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investigated and thus we have layed the groundwork here for important future studies. Thus, 
B cells could next be manipulated during iGB culture via retroviral transduction to express 
pro- and anti-inflammatory cytokines to study activation and pathogenic potential in EAE. 
Moreover, limitation of low B cell survival can be overcome to study activation in intestinal 
segments.  
Overall, it is very important to better understand the different roles B cells can play during 
EAE and MS pathogenesis in order to further improve treatment options in MS, since B cell 
depletion therapies are not always successful for all patients and can be accompanied by 
serious side effects.  
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